## Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>3</td>
</tr>
<tr>
<td>Matthias Weber, Swiss Reinsurance Company</td>
<td></td>
</tr>
<tr>
<td>Joseph Brain, Harvard School of Public Health</td>
<td></td>
</tr>
<tr>
<td>SEARCH – The search for health data and insights from rapidly changing economies</td>
<td>5</td>
</tr>
<tr>
<td>Christoph Nabholz, Swiss Re Centre for Global Dialogue</td>
<td></td>
</tr>
<tr>
<td>Simon Woodward, Swiss Re Centre for Global Dialogue</td>
<td></td>
</tr>
<tr>
<td>Closing the financial gap for cardiovascular disease in China</td>
<td>13</td>
</tr>
<tr>
<td>Xiaojie Wang, Swiss Reinsurance Company</td>
<td></td>
</tr>
<tr>
<td>David Lu, Swiss Reinsurance Company</td>
<td></td>
</tr>
<tr>
<td>Hueyfang Chen, Swiss Reinsurance Company</td>
<td></td>
</tr>
<tr>
<td>Lost life expectancy due to air pollution in China</td>
<td>27</td>
</tr>
<tr>
<td>Douglas W. Dockery, Harvard School of Public Health</td>
<td></td>
</tr>
<tr>
<td>C. Arden Pope III, Brigham Young University</td>
<td></td>
</tr>
<tr>
<td>Overview of health risk factors in Brazil</td>
<td>35</td>
</tr>
<tr>
<td>Marcia C. Castro, Harvard School of Public Health</td>
<td></td>
</tr>
<tr>
<td>Understanding the global risk of the tobacco epidemic and its trajectory in an emerging market nation</td>
<td>41</td>
</tr>
<tr>
<td>Hillel R. Alpert, Harvard School of Public Health</td>
<td></td>
</tr>
<tr>
<td>Chronic diseases in India: Burden and implications</td>
<td>51</td>
</tr>
<tr>
<td>K. Srinath Reddy, Public Health Foundation of India</td>
<td></td>
</tr>
<tr>
<td>Sailesh Mohan, Public Health Foundation of India</td>
<td></td>
</tr>
<tr>
<td>The nutrition transition in India: Trends in dietary intake and associations with cardiometabolic outcomes</td>
<td>59</td>
</tr>
<tr>
<td>Shilpa Bupathiraju, Harvard School of Public Health</td>
<td></td>
</tr>
<tr>
<td>Health risk factors in the adult Mexican population</td>
<td>69</td>
</tr>
<tr>
<td>Hiram Beltrán-Sánchez, University of Wisconsin-Madison</td>
<td></td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>77</td>
</tr>
<tr>
<td>Sponsors</td>
<td>78</td>
</tr>
</tbody>
</table>
Dear reader

We are very pleased to welcome you to this edition of the Risk Dialogue Series on Health Risk Factors in Rapidly Changing Economies.

This compendium features articles that analyse time trends and developments of key risk factors associated with the increasing prevalence of chronic, non-communicable diseases (NCDs) seen in major emerging markets around the world. The health profile of these countries is changing swiftly and significantly. As economies grow, as infectious diseases decrease, and as lifespan increases, there is an increase in NCDs. The incidence of cardiovascular diseases, stroke, diabetes, cancer, accidents, and mental health issues are rising rapidly, providing a major challenge for providers and funders of health care. The prevalence and costs to the health care system is a concern to insurers and public health officials alike.

The SEARCH – Systematic Explanatory Analyses of Risk factors affecting Cardiovascular Health – collaboration is a joint undertaking between the Harvard School of Public Health (HSPH) and Swiss Re. The articles presented in this compilation are by HSPH faculty members, their research fellows and Swiss Re colleagues. The extensive research conducted and summarised in the articles were conducted primarily during the 100th anniversary of HSPH and the 150th anniversary of Swiss Re.

We hope these papers provide insightful data and analyses into the major health trends confronting some of the most populous nations on the planet; we intend that these articles will inspire both private and public sectors to seek ways in which we can most effectively manage the NCD pandemic.

With best regards

Matthias Weber  
Group Chief Underwriting Officer  
Member of the Executive Committee  
Swiss Reinsurance Company

Joseph Brain  
Drinker Professor of Environmental Physiology  
Harvard School of Public Health

With best regards
Emerging markets have undergone a dramatic transformation over recent decades. They have typically developed from largely rural, agricultural societies to manufacturing and service providing urban powerhouses. Less publicised, but equally significant has been the shift in their health profiles. Emerging markets have been largely successful in ridding themselves of communicable diseases; only to be confronted by a pandemic of chronic, non-communicable diseases (NCDs) putting significant strain on health care systems. Public and private health care providers both need to develop effective responses to this pandemic.

### Shift in health profiles

Pre-industrial societies typically experience conditions of under- or malnourishment. What food is available consists of staple cereal or vegetable crops. Diets are most likely low in animal products, processed foods and sugar. Providing both for food and family needs requires intense physical effort. Health provisions and medicines are likely to be basic. Doctors are few and far between. Many early deaths are likely to occur from preventable conditions, particularly around childbirth. Sanitation may be sparse or minimal, living close to livestock, with no guarantee of clean water. In these conditions, communicable diseases can flourish. These include influenza, tuberculosis, hepatitis, measles and Ebola among others.

Health drivers have shifted as countries have industrialised and urbanised. Many of the conditions that allow communicable diseases to flourish have been corrected or eradicated in emerging markets. Water supplies and sanitation have improved. There has been a significant reduction in the number of people living close to livestock. Health services have developed significantly in large cities where citizens have access to doctors and hospitals. Childbirth has become safer.

In a short space of time, emerging markets have gone from conditions of hard physical work and scarcity to conditions of sedentary work and plenty.

Food – and a large choice of food – has become readily available. Diseases of malnourishment – which frequently weaken immune systems and leave individuals vulnerable to other conditions – have been consigned to the past. However, societies are moving from the challenge of under- to over nourishment. The nature of that nourishment has shifted from high fibre staples to more processed foods, more animal produce and a significantly higher intake of sugar. Supplementing food, populations have greater access to tobacco and alcohol, both with serious effects on health. Work has frequently become more sedentary, in the form of computer, clerical or light manufacturing work. Lifestyle has also become more sedentary with convenience goods and cars reducing the need for physical exertion.

The net result has been a pandemic of NCDs in emerging markets. Most common amongst these is cardiovascular disease; hence the concentration in the SEARCH project - Systematic Explanatory Analyses of Risk factors affecting Cardiovascular Health - on the drivers of cardiovascular conditions. However, those drivers affect a wide, and often related, range of other NCDs, including cancer, respiratory diseases and diabetes.

These very different diseases have common qualities. Infectious conditions, while frequently severe, tend to be acute. NCDs are generally chronic conditions, often managed for many years, and in many cases requiring high levels of medical care. Moreover, while the very young and very old are more vulnerable to most communicable diseases, NCDs are concentrated among older age groups. One of the consequences of urbanisation and industrialisation has in most countries been a decline – a sometimes dramatic decline – in the birth rate. Because there has also been a drop in the death rate, as communicable diseases become less common, all emerging markets are beginning to age – some quite rapidly.
The four countries studied in the SEARCH research project - Brazil, China, India, Mexico – account for nearly three billion people, or 42% of the world’s population.

All of these trends are occurring in the most populous nations in the world. The four countries studied in the SEARCH research project – Brazil, China, India, Mexico – account for nearly three billion people, or 42% of the world’s population. Within the broad trends of the NCD epidemic, there is considerable geographic variation. No two countries are exactly alike.

In China, Type 2 diabetes was very uncommon in the 1980s, almost unknown in much of the country; it now has a prevalence of 11.6% in the adult population, narrowly overtaking the prevalence rate of the US in just twenty years. In 2013, the United Nations Food and Agricultural Organisation estimated that Mexico surpassed the US in its obesity rate at 32.6% of the population.

As a result, these markets are rapidly moving towards patterns of deaths more reminiscent of developed markets. This can be seen most clearly in China, with cancer and heart disease deaths comparable to the US (see Figure 1). There are proportionally more stroke deaths in China than the US; however, these can be expected to fall with medical progress. Other countries such as Brazil and Mexico are transitioning towards the US death patterns, but more slowly; notable in this context is the high incidence of diabetes in Mexico (see Figure 1). India is furthest from the US; communicable infectious diseases are more prevalent in India. NCDs – such as cancer, stroke and heart diseases – are typically more costly for insurers and public health authorities. As demonstrated in Figure 1, NCDs increase significantly as people become older. When looking at the four country profiles, cardiovascular diseases and stroke stand out.

In China, Type 2 diabetes was very uncommon in the 1980s, almost unknown in much of the country; it now has a prevalence of 11.6% in the adult population, narrowly overtaking the prevalence rate of the US in just twenty years. In 2013, the United Nations Food and Agricultural Organisation estimated that Mexico surpassed the US in its obesity rate at 32.6% of the population.

Emerging markets are rapidly moving towards patterns of deaths more reminiscent of developed markets.
The SEARCH study aims to provide an overview of the drivers of NCDs within these countries, together with the responses of public health authorities.

Figure 1: Causes of death in 2010 in age intervals 25–69 years in selected countries (% total mortality by age band)

Notes: In the younger age bands, transport injuries are the leading cause of death, but then quickly declines in the older age bands. The key differences observed in the country profiles compared to the USA are: Brazil has a higher stroke death rate (13% vs 4%; age band 50–69); India has a high death rate due to communicable diseases (30% communicable diseases, 10% injuries; 60% non-communicable diseases; across all age groups) and has high lung disease or COPD (chronic obstructive pulmonary diseases) death rate (16% vs 7%; age band 50–69); China has a heart disease mortality rate which is lower than in the USA (15% vs 24%; age band 50–69), while death due to stroke is significantly higher in China (19% vs 4%; age band 50–69); Mexico stands out with a high diabetes death rate (14% vs 4%; age band 50–69).

Source: Global Burden of Disease 2010
In this publication is a selection of articles reflecting the breath of different risk factors addressed by SEARCH in four countries.

Country health profiles

A large number of articles have been contributed by the researchers from HSPH and Swiss Re, which will all be featured in four country specific publications. In this compendium publication, we have picked a selection of articles reflecting the breath of different risk factors addressed by SEARCH in the four countries. The following articles have been included:

China

The leading cause of death in China is currently cardiovascular disease (CVD). As Wang, Lu and Chen report, it accounts for 41% of all deaths every year, which in a country as vast as China, accounts for one death every ten seconds. As China faces rapid population ageing, medical treatment costs of CVD – both acute hospital expenses and long term healthcare expenditures – are likely to rise significantly. Non-medical costs associated with CVD events, such as loss of income, also contribute to the significant financial distress of patients. This will stretch provision of health care services, which officially became universal in 2009, despite significant regional differences. While the reform of the essential medicines system has reduced high out-of-pocket medicine spending, a significant gap still exists for which private insurers can offer financial protection.

Rapid urbanisation in China has had detrimental effects on air quality, not least because modern pollutants, such as car exhaust fumes, frequently mix with smoke from heavy industry, domestic coal burning and power production. China in recent years has seen unprecedented levels of air particulate pollution in some cities, as described by Dockery and Pope. Air pollution in China is estimated to have contributed to 1.2 million premature deaths. Lifetime exposure to air pollution in Beijing, for example, is estimated to reduce life expectancy by around three years.

Brazil

Public health authorities can have a considerable influence over health trends. In Brazil, according to researcher Marcia Castro, there were a number of successful campaigns against communicable diseases. The legacy of this success influences public policy towards NCDs. Brazil was one of the foremost countries in anti-smoking legislation. Efforts are underway to encourage healthier eating and more exercise; although confronted by an ageing population, the challenges of confronting the NCD epidemic are considerable.

One of the ironies of Brazil is that, while it is clamping down on domestic tobacco consumption, it is the leading global exporter of tobacco, according to researcher Hillel Alpert. The Brazilian authorities have succeeded in reducing smoking prevalence – through a mixture of price increases, advertising bans and graphic warnings – by 50% since 1989. However, given the size of Brazil, there are still some 25 million smokers. Moreover, a core group of young people – which includes more women than men – continues to take up smoking. The widening of social globalisation of young people may yet have a positive impact on tobacco prevalence among the young.
India

Authors Reddy and Mohan highlight how India is on the cusp of health change. It has both extensive recent urbanisation; with continuing widespread near-subsistence agriculture in basic conditions. Infectious disease is still a serious public health concern; but the spread of NCDs is rapid. The number dying from CVD per year is estimated at 2.7 million, higher in absolute terms than China. Diabetes has spread so rapidly that India, with an estimated 65 million sufferers, has been typecast as the ‘diabetes capital of the world’.

The spread of diabetes has mainly been related to changes in diet, as noted by researcher Shilpa Bupathiraju. India’s population has moved from a diet of whole grains and vegetables to one rich in processed food, added fats and sugars. This nutritional change has occurred at a faster pace than in developed economies. The economic impact of this sudden transition is huge; and the public health authorities are struggling to respond to this preventable condition.

Mexico

India may have more diabetics than any other country, but Mexico, fuelled by a severe epidemic of obesity, is also facing significant challenges due to the prevalence of diabetes. In his article, Beltran-Sanchez shows that Mexico has undergone considerable dietary change over the past decade. Notable for Mexico is the high presence of sugary drinks in a country where drinking water quality can be poor. The authorities are taking steps to address dietary changes, notably being the first country in the world to implement a ‘soda tax’. Nonetheless, the challenge is considerable; not least because Mexico has a young demographic and their rates of obesity are rising.

NCDs – moving towards health care solutions

From what we know of developed markets, there is no silver bullet for NCDs. No single measure can be taken to reverse their virulent spread. In some ways, NCDs are more insidious than infectious diseases. In order to stop an infectious disease, one has to neutralise the source of the infection; or to develop immunity. Both of these have been achieved with some measure of success in all countries studied. NCDs, however, are frequently lifestyle diseases. Their likelihood is substantially reduced by not smoking, eating healthier and increasing physical activity. The challenge is to persuade individuals to do these things; and to provide treatment for those already with NCDs.

These are massive challenges. They are not entirely insurmountable. Brazil has shown clearly how a multi-agency approach to a multi-faceted challenge can be achieved, eg by reducing cigarette consumption in the country. It is one piece to a large puzzle, but an important piece nonetheless.

The challenge for policy makers is threefold: public health campaigns to address the causes of NCDs, health care facilities to treat them and funding are needed.

Funding NCD treatment is a major issue, particularly as costs are currently concentrated on individuals.

The costs of NCDs can be financially ruinous to those in emerging markets who suffer from them. Health or life insurance penetration in all four countries studied is low. If public health provision, as is often the case, proves insufficient, then treatment expenses must be met out of pocket. That may impact not only the sufferer, but the family members that support them. There are knock-on implications. Those with NCDs may avoid going to see a doctor when an earlier visit could have led to a more cost effective treatment. Potential health costs may also encourage a savings culture – which is not always a bad thing, but one that can be taken to extremes. Some Asian economies show macro-economic distortions with the amount of savings being drained away from everyday spending.
Insurance can be a cost effective way of funding necessary health treatments.

Private insurance can be a cost effective way to provide protection to individuals in the face of ill health. Within an efficient regulatory system, insurers can be one means of helping control health care costs. Together with other public and private initiatives, it can be one of the pillars within a well-functioning health system – a system which can react and to a degree manage the NCD pandemic confronting emerging markets.

SEARCH and NCDs

The starting point for both private and public actors in tackling the NCD epidemic is information. For public health authorities, it informs them where they can best distribute their preventative measures and budget; and points to the best allocation of public health care resources. SEARCH is a valuable tool in assessing both the epidemiological spread of NCDs based on new data and the latest literature reviews; and the effectiveness of some of the responses to NCDs.

For insurers, data and information is a vital part of their business model. It allows them to create sustainable risk pools and set premiums that reflect the risk posed by individuals in the pool. Traditionally, such actuarial assumptions have been based on past data tables. This approach will not be thrown out; however, the speed and scale of the NCD epidemic in emerging markets will also cause actuaries to cast an eye forwards to the potential outcomes of current health trends. Here, SEARCH is a valuable tool in placing past data tables alongside the latest epidemiological research.

The joint SEARCH research project, between Swiss Re and the Harvard School of Public Health is designed to provide insights and tentative conclusions to one of the biggest challenges facing the most populous countries in the world. Recent economic and societal changes have been profound in Brazil, China, India and Mexico. The effects of these changes on health should not be overlooked.
References

About the authors

Christoph Nabholz
Christoph Nabholz is Head of Business Development at the Swiss Re Centre for Global Dialogue. With his background in genetics, he actively supports Swiss Re’s R&D activities in medical trends and longevity research. Prior to joining Swiss Re, he was a postdoctoral fellow in genomics and functional genomics at Harvard University and has a Ph.D. in molecular genetics from the University of Freiburg, Switzerland.

Simon Woodward
Simon Woodward is a Senior Business Development Manager at the Swiss Re Centre for Global Dialogue. Simon is a graduate of St. Antony’s College, Oxford and previously worked as an economic and political analyst. He worked in the communications department of reinsurer Converium before coming to Swiss Re.
Closing the financial gap for cardiovascular disease in China

Cardiovascular Disease (CVD) is the leading cause of mortality and morbidity in China. The medical cost of CVD has been trending upwards at varying rates by geographic location over the past six years, and is projected to increase further in the future. Currently, over 90% of the population in China is covered by the social healthcare system that went through a recent reform in 2009. However, insurance coverage on CVD remains a major challenge and is putting the Chinese population at risk. It is expected to cause even more significant economic burden in the future.

Introduction

Cardiovascular disease (CVD) has been the leading cause of mortality and morbidity in China in recent years. In 2010, 1.7 million people in China died from stroke and another 0.9 million died from ischemic heart disease. According to a 2012 report on cardiovascular diseases in China, around 41% of total deaths could be attributed to CVD every year. In China, it is estimated that there is one CVD death every 10 seconds.

According to our findings during the Systematic Explanatory Analyses of Risk factors affecting Cardiovascular Health (SEARCH) project, CVD risk factors such as hypertension, tobacco smoking, alcohol use and an unhealthy westernised diet have been trending upwards over the last 20 to 30 years. In Moran’s model, it was estimated that the projected number of annual cardiovascular events will increase by more than half from 2010 to 2030, even if we only account for ageing and population growth factors. In short, China is facing a fast growing financial burden due to CVD in the coming decades.

China announced nationwide healthcare reform in 2009 in order to achieve universal access to healthcare services and reduce the economic burden of medical expenses for its citizens. Recently, more and more attention has been focused on evaluating the current social health insurance system in China. In this paper, we are going to estimate the financial protection gap for CVD in China by analysing the medical expenses of CVD and financial protections provided by existing insurance.

In this paper, the authors estimate the financial protection gap for CVD in China by analysing the medical expenses of CVD and financial protections provided by existing insurance.

Current health insurance coverage

The social health insurance system in China consists of three schemes: the new rural cooperative medical care system (NRCMS) for rural residents, the urban employee basic medical insurance (UEBMI) for urban residents employed by state-owned/private enterprises and urban resident basic medical insurance (URBMI) for the other urban residents (eg the urban unemployed, self-employed, elderly and students). The coverage varies across the three schemes and regions, and it is seen as the government’s attempt to narrow the financial gap by providing reimbursement for not just CVD-related costs, but also for general healthcare spending. On top of providing insurance to its citizens, the government also has established various programmes to control medical and drug costs in hospitals. China has set the goal to achieve universal health care coverage for all its citizens by 2020.
Regional differences
The inequality in China’s health care system still exists due to the uneven development across regions. In general, UEBMI’s benefits are better than the other two schemes due to its stronger financial base derived from contributions by both employers and employees. In contrast, URBMI and NRCMS are more heavily dependent on government subsidies and hence, wealthier regions tend to have better coverage. Since we did not find specific CVD-financial protection data, the publications for general diseases were used for discussion in this section. We believe that the coverage for general diseases should provide a good overview of what might be the financial protections available for CVDs under China’s healthcare system. At any rate, we believe using the general diseases coverage is optimistic as CVDs medical costs are higher than average medical costs, and there are new and innovative treatments for CVDs that are likely not covered by the current system.

Huang summarised the inpatient and outpatient coverage under UEBMI and URBMI for each province in China based on a report from the Ministry of Human Resources and Social Insurance in 2010 (Figures 1, 2). Employees in Beijing, Tianjin and Shanghai must cover 60–70% of the medical expenses out of pocket; this reflects the big gap between social insurance cover and the higher medical expenses in these big cities. The research suggests that the reimbursement rates under NRCMS are lower than URBMI. According to this study, the provincial average of inpatient reimbursement rates is around 70% for UEBMI and 55% for URBMI. The provincial average of outpatient reimbursement amount is around 100 RMB for UEBMI, one-third higher than for URBMI. It is reasonable to assume that reimbursement rates for patients with CVDs are lower than average due to more advanced and complicated treatments with costs that could reach the cap much faster. In addition, outpatient costs for CVDs would have less coverage compared to the average due to the expensive long-term medicine cost associated with CVDs.

Figure 1: Inpatient reimbursement rates of UEBMI and URBMI by province in 2010 as a percent of total expenses

Source: Huang (2010)
Meng et al. conducted research on health service accessibility and financial protection for general diseases based on the 2011 National Health Service Survey (Figure 3). To study the regional differences, data were split into urban or rural areas and three geographic regions: east, central, and west (Figure 4). By 2011, health insurance coverage, including both social and commercial insurances, was provided to over 90% of the population nationwide. Compared to urban areas, rural areas cover a wider population but reimbursement rates are lower. The inpatient reimbursement rates range from 40%–55%; the difference is mainly due to different health schemes.
Catastrophic health expense was defined as spending 40% or more of total income on healthcare. Meng et al also indicated that little improvement was observed on the percentage of households having catastrophic health expenses during the period 2003–2011. Although reimbursement caps have increased almost twice as much on average since 2007, catastrophic health expenses still remain a concern. Inpatient self-discharge rates due to financial stress were on average 28.8% nationwide, and even in the richest region, the rate was still close to 20%. Some experts believe the percent of households experiencing catastrophic health expenses is expected to be much higher than the numbers in this paper, especially in rural areas. It is also interesting to note that the percentage of households with catastrophic health expenses does not vary much between urban and rural areas, which indicates that urban residents are subjected to similar catastrophic health expense risks as rural residents.

Although the findings from this study apply to general disease, we could reasonably infer that CVD trends are similar if not worse.

**Medicine coverage**

Due to significant expenditure on medicine, China reformed the essential medicines system in 2009 to reduce high out-of-pocket spending on medicine9–11. The latest essential drug list (EDL) was released in 2013, which includes 317 western medicines and 203 traditional Chinese medicines. The drugs on EDL have higher reimbursement rates than non-essential drugs and are categorised into two groups – List A and List B. List A comprises lower-priced and the most frequently used drugs (mostly generic) and are fully reimbursed. Drugs on List B are often higher priced and include patented and innovative drugs; the selection of drugs on List B can be adjusted by provinces and municipalities to suit their local economic situation and healthcare needs. The reimbursement level for List B drugs also varies across province governments. It was found that wealthier provinces added more drugs to their provincial EDLs9. The NRCMS covers significantly less drugs than the urban healthcare schemes9.
In this section, we narrow our focus to concentrate on medical costs and components associated with CVD, and the financial protection gap that is still yet to be closed. Due to data availability, the focus is on coronary heart disease (heart attack and heart failure) and cerebrovascular disease (stroke). In 2011, the total inpatient expenses in China were about RMB 50 billion for acute myocardial infarction, RMB 140 billion for cerebral haemorrhage and RMB 270 billion for cerebral infarction. This translates to about USD 75 billion in aggregate. In this section, we studied the CVD medical expense, including the various cost components, trends, and variances by regions, age and gender.

Components of CVD medical expenses

The economic burden of CVD includes both short-term and long-term direct costs as well as indirect costs. All inpatient costs, including drugs during that period, could be grouped into the short-term direct costs category, which contribute to the majority of the total CVD medical expenses. The long-term direct costs consist of medication after hospital discharge, follow-up outpatient service, nursing at home etc. Indirect costs are associated with the impairment of work and life activities, such as loss of income due to short term sick leave from work, or permanent leave such as early retirement.

Researchers found that about 60% of the cost incurred after a stroke was during the acute hospitalisation phase, and 40% was during the first year after discharge. Medicine was the biggest driver of costs.

Hu analysed the direct cost components of atrial fibrillation (AF) related stroke in China (Figure 5). The average total direct cost of AF-related stroke was about USD 6000 per patient-year. About 60% of the cost was incurred during the acute hospitalisation phase, and 40% during the first year after discharge. This shows that the financial burden on medical costs continues to be significant, not just when the patients were first diagnosed with the disease and were hospitalised, but it remains for many months even after the patients are discharged from the hospital. Among all costs listed by Hu, the major cost driver is medicine. More than half of total direct costs in both the short-term and the long-term can be attributed to drug costs. The indirect cost was more than half of the direct cost, and 63% of the total indirect cost was associated with early retirement. This indicates that besides medicine costs, loss of income is another big component of total costs associated with CVD. Sun et al. also did statistical analysis on inpatient CVD medical cost. They found that about 40% of inpatient costs come from medicines, which was consistent with Hu’s research.

Figure 5: Direct and indirect costs components of AF-related stroke

Source: Hu (2013)
AF-related stroke patients are expected to pay more than 50% of their associated medical costs.

Geographic variances of CVD medical costs are mostly caused by the disparities in economic development and different social insurance coverage.

Limited accessibility to quality healthcare services in rural areas may be forcing patients to seek care beyond the local hospitals and results in additional costs.

As discussed above, current public insurance schemes reimburse around 50% of inpatient costs, excluding drugs, which represent about 20% of the total direct costs of AF-related stroke. The coverage for medicine cost varies significantly between regions and schemes. With less coverage for the more recent, innovative, and imported Western drugs, the average reimbursement rate for CVD drug cost could be lower than 50%. Therefore, AF-related stroke patients are expected to pay more than 50% of their associated medical costs. In addition to that, there is currently no coverage for any of the indirect costs incurred due to sickness, which could be as high as 50% of total direct costs.

Geographic variances
Geographic variances of CVD medical costs are mostly caused by the disparities in economic development and different social insurance coverage. In this part of study, we analysed the ratio of health expenditure to the annual expenditure by region. Since there is no specific CVD-expenditure data in the China Health Statistical Yearbook, we used the data for overall medical expenses.

Figure 6 shows that the ratio of annual health expenditure to total expenditure per capita ranges from 4%–9% for urban areas and 5%–13% for rural areas. In general, people in rural areas spend relatively more on healthcare than people from urban areas. The less-developed provinces, such as Jilin and Shanxi, usually have above-average health expenditure percentages, especially in the rural areas. They also tend to exhibit higher disparity between urban and rural healthcare spending. This suggests that limited accessibility to quality healthcare services in rural areas forces patients to seek care beyond the local hospitals and results in additional costs (e.g., transportation, room and board etc). These costs need to be carefully accounted for when developing a viable solution for rural residents to close the financial gap on CVD medical expenses or even general medical expenses. Of all provinces, only Qinghai shows a reverse trend of higher health expenditure ratio in the urban versus rural area. One explanation could be that politics sometimes determines the level of social healthcare benefits. Provinces like Qinghai, with small populations and concentrated ethnic minorities, receive more subsidies from the central government to ensure they have better financial protection14.

Figure 6: Regional health expenditure comparison

Source: China Health Statistical Yearbook (2013)
For the comparison, we focus on the biggest cities in China, where there is generally good healthcare access and plenty of opportunities for private insurance carriers. We chose four cities/provinces, one from each region (Table 1) to compare the variances between the North (Beijing), South (Guangdong), East (Shanghai) and West (Chongqing) of China. Chongqing, being the smallest city among the four, has the highest health expenditure/annual expenditure per capita in its urban area, even though its absolute amount of health expenditure is at the lower end.

<table>
<thead>
<tr>
<th>Regions</th>
<th>Urban 6.9%</th>
<th>Rural 9.3%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing</td>
<td>6.9%</td>
<td>9.3%</td>
</tr>
<tr>
<td>Shanghai</td>
<td>4.5%</td>
<td>8.2%</td>
</tr>
<tr>
<td>Guangdong</td>
<td>4.7%</td>
<td>5.9%</td>
</tr>
<tr>
<td>Chongqing</td>
<td>7.0%</td>
<td>8.3%</td>
</tr>
</tbody>
</table>

Source: China Health Statistical Yearbook (2013)

This suggests that even among the big cities, healthcare expenditure as a percentage of average annual expenditure differs and hence, there could be bigger financial gaps observed in such cities. Such areas could be a good market for private health insurance to step in and offer additional protection. Comparing the north and the south, people from Beijing spent more on healthcare compared to people from Guangdong. The figure for Guangdong could be attributable to the better insurance coverage in those areas. This is consistent with the findings shown in Figure 1 – ie the inpatient reimbursement rates from social healthcare schemes for urban residents are higher in Guangzhou than Beijing. Although Chongqing has a similar inpatient reimbursement level for urban areas as Guangzhou, its residents spend much more on health care than Guangzhou residents. It is not clear why this is the case.

In urban areas, it is projected that the average CVD inpatient costs are around 130% of annual expenditure per capita, while in rural areas, the ratio increases to 230%.

In Figure 7, we compared CVD inpatient medical costs and annual expenditure per capita for both urban and rural areas. According to the definition in the China Health Statistical Yearbook 2013, the urban areas include municipality districts and prefectural-level districts, while the rural areas include county-level cities, counties, towns and villages. CVD inpatient medical costs were significantly higher than annual expenditure per capital in both urban and rural areas. In urban areas, it is projected that the average CVD inpatient costs are around 130% of annual expenditure per capita, while in rural areas, the ratio increases to 230%. This creates a significant financial burden to people with CVD, even if we apply a 50% reimbursement rate under the current public health scheme. Although people in rural areas spend less in terms of annual expenditures and inpatient medical costs, they are more vulnerable after being hit by CVD due to the higher ratio of inpatient medical cost to annual expenditure.

Source: China Health Statistical Yearbook (2013)
Hospital stays are longer among urban residents compared to rural residents. Studies also find that hospital stays are longer among urban residents compared to rural residents (Figure 8), which suggests that rural residents could be receiving inadequate healthcare due to financial hardships. If this is the case, personal private insurance might not be the right solution as rural residents would not be able to afford it. However, government could pair up with large re/insurance companies to design additional affordable healthcare solutions for rural residents, while encouraging urban residents to purchase additional personal private insurance from local insurance providers in order to close the protection gap. This could save significantly reduce government healthcare expenditures, while providing adequate medical financial protection to all citizens.

![Figure 8: 2012 CVD-specific inpatient days between urban and rural areas](image)

Source: China Health Statistical Yearbook (2013)

**CVD medical cost trends**

Six years of annual inpatient medical cost data for five major cardiovascular diseases from the China Health Statistical Yearbook were analysed. The total inpatient medical cost for those CVDs, except coronary artery bypass grafting (CABG), includes the expenses for examination, treatment, medicine and hospital stays. CABG includes the additional surgery expense. The compounded annual increase rates for each disease are shown in Table 2.

<table>
<thead>
<tr>
<th>Diseases</th>
<th>Urban/Rural Ratio</th>
<th>Urban</th>
<th>Rural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myocardial infarction</td>
<td>1.7–4.1</td>
<td>20,000–30,000</td>
<td>7,000–12,000</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>1.6–3.2</td>
<td>10,000–16,000</td>
<td>5,000–6,000</td>
</tr>
<tr>
<td>Coronary Artery Bypass Grafting</td>
<td>0.9–1.4</td>
<td>35,000–50,000</td>
<td>36,000–40,000</td>
</tr>
<tr>
<td>Cerebral hemorrhage</td>
<td>1.3–2.1</td>
<td>16,000–20,000</td>
<td>10,000–13,000</td>
</tr>
<tr>
<td>Cerebral infarction</td>
<td>1.4–2.8</td>
<td>10,000–15,000</td>
<td>5,000–7,000</td>
</tr>
</tbody>
</table>

Source: China Health Statistical Yearbook (2013)
The average annual cost increases for acute myocardial infarction, congestive heart failure, and cerebral haemorrhage were around 8% to 11%, which were higher than the annual inflation rate of 4%. Despite the average inflation rate of 4%, the inpatient medical cost for CABG remained stable over the past six years. One explanation for this is that such surgery becomes a more mature procedure and its cost is controlled by the government, which leads to higher efficiency and lower costs. After the 2009 healthcare reforms, the increase of CVD inpatient cost slowed which could be attributed to the cost-effective control by governments (Figure 9).

### Table 3: Six year trend of annual CVD inpatient medical cost per capita in China

<table>
<thead>
<tr>
<th>Year</th>
<th>Acute Myocardial Infarction</th>
<th>Congestive Heart Failure</th>
<th>Cerebral Hemorrhage</th>
<th>Cerebral Infarction</th>
<th>Coronary Artery Bypass Grafting</th>
<th>CPI Inflation**</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>11602</td>
<td>4179</td>
<td>8481</td>
<td>5990</td>
<td>36429</td>
<td>6.58%</td>
</tr>
<tr>
<td>2008</td>
<td>12566</td>
<td>4512</td>
<td>8489</td>
<td>6047</td>
<td>34819</td>
<td>1.26%</td>
</tr>
<tr>
<td>2009</td>
<td>14271</td>
<td>5067</td>
<td>9958</td>
<td>6874</td>
<td>38574</td>
<td>1.70%</td>
</tr>
<tr>
<td>2010</td>
<td>15774</td>
<td>5896</td>
<td>11020</td>
<td>7143</td>
<td>40071</td>
<td>4.57%</td>
</tr>
<tr>
<td>2011</td>
<td>16793</td>
<td>6732</td>
<td>11802</td>
<td>7325</td>
<td>38802</td>
<td>4.06%</td>
</tr>
<tr>
<td>2012</td>
<td>16802</td>
<td>7148</td>
<td>12207</td>
<td>7241</td>
<td>34836</td>
<td>2.41%</td>
</tr>
</tbody>
</table>

**Average Annual Increase Rate:**
- Acute Myocardial Infarction: 8%
- Congestive Heart Failure: 11%
- Cerebral Hemorrhage: 8%
- Cerebral Infarction: 4%
- Coronary Artery Bypass Grafting: −1%
- CPI Inflation**: 4%

Note: Data for 2007 was used as the base in the accumulative increase rates.

Source: China Health Statistical Yearbook (2013)
Financial protection gap of cardiovascular diseases

Generally speaking, the medical expenses for CVDs include both short-term and long-term direct costs as well as indirect costs. The largest portion of short-term direct cost comes from inpatient costs, about half of which are paid out-of-pocket. Considering the high cost of CVDs, those medical costs beyond the social insurance coverage represent the gap to be filled by medical reimbursement insurance. The longitudinal study from CHARLS Research Team\(^7\) indicated that only 7% of the wealth of the older population (aged 45 and over) is held in liquid assets such as cash, while the majority of their wealth is in the form of property (73%). When facing large out-of-pocket expenses for CVDs, patients might be forced to sell their properties.

Huffman et al\(^8\) included participants aged 25–70 from Beijing and Henan Zhoukou City and collected data in 2008–2009 to assess the economic impact of CVD. They split the survey participants into three groups by income level using the national population income distribution: low (poorest 40%), middle (middle 40%) and high (top 20%). The low income group had the highest out-of-pocket proportion of annual household expenditure and the highest percentage of income loss, although in absolute terms, their income losses were the smallest. The financial gap was the biggest for the low income group, followed by the middle income group; the gap was the smallest for the high income group. The high saving rate in urban areas, an estimated 30% of disposable income\(^9\), indicates that middle and high income groups can use their savings to reduce the financial distress caused by CVD. According to the Swiss Re Asia Medical Survey 2014\(^20\), the top two barriers to purchasing personal medical reimbursement insurance in China are lack of knowledge and affordability.

### Table 4: CVD expenditures and income effects among different income strata

<table>
<thead>
<tr>
<th></th>
<th>Low</th>
<th>Middle</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient expenditures/Total CVD expenditures, %</td>
<td>77.2</td>
<td>77.5</td>
<td>82.1</td>
</tr>
<tr>
<td>15-month out-of-pocket CVD expenditures as a proportion of annual total household expenditures, %</td>
<td>40.1</td>
<td>30.5</td>
<td>15.0</td>
</tr>
</tbody>
</table>

**Income Effects**

<table>
<thead>
<tr>
<th></th>
<th>Low</th>
<th>Middle</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any decrease in individual income, %</td>
<td>45.5</td>
<td>24.4</td>
<td>13.1</td>
</tr>
<tr>
<td>Any decrease in household income, %</td>
<td>40.9</td>
<td>25.6</td>
<td>14.3</td>
</tr>
<tr>
<td>Decrease in individual monthly income since hospitalisation, INT$*</td>
<td>73.3</td>
<td>122.2</td>
<td>244.4</td>
</tr>
<tr>
<td>Median decrease in household monthly income since hospitalisation, INT$</td>
<td>85.6</td>
<td>122.2</td>
<td>342.2</td>
</tr>
</tbody>
</table>

*INT$ is international dollars

Source: Huffman (2011)\(^8\)

Another finding from the Swiss Re Asia Medical Survey 2014\(^20\) is that the top two criteria for patients in China when selecting a hospital are quality of treatment and the reputation of the hospital. Compared with patients in other Asian countries, such as India and Thailand, Chinese patients put the most weight on reputation and have a higher propensity to purchase commercial reimbursement products. The hospitals with the highest reputation in China are mostly in metropolises like Beijing and Shanghai. Currently, cross-provincial reimbursement systems are lacking which enable patients from other provinces to seek better treatment in these cities. Moreover, some advanced medical treatments for CVDs are only available or have higher successful rates in developed countries, such as the US. However, the medical costs for these advanced overseas treatments are extremely high. For example, the average cost of a heart transplant in the US is about USD 787 000 due to the complicated procedure and procurement of the organ\(^21\). If commercial...
Commercial insurance could meet the needs of Chinese patients by providing coverage for non-essential drugs, especially patented and innovative drugs, and imported medical devices.

Insurance could provide the coverage for these expensive overseas therapies as well as the living expenses during medical tours, it would ease the financial burden for the insured if they choose overseas treatments. Therefore, there is an increasing need to provide insurance for patients in China that covers cross-regional and overseas medical costs.

Current social medicine policies state that EDL drug revenues are required to reach 25%–40% of total revenues in medium-sized hospitals, where middle and high-income groups are most likely to seek healthcare service. Around 60–75% of drugs prescribed by those hospitals have high prices and low reimbursement rates. Moreover, the quality of imported medical devices for heart surgeries are usually higher than domestic devices and receive partial medical reimbursement, eg cardiac pacemakers, vascular stent, heart valves etc. One study indicated that only up to 25% of patients who need to use high priced treatments for diseases can afford those treatments. When it comes to CVDs, the percentage is expected to be no more than 25%. Therefore, commercial insurance could meet the needs of Chinese patients by providing coverage for non-essential drugs, especially patented and innovative drugs, and imported medical devices.

Care-seeking behaviours are strongly associated with insurance accessibility and affordability. A study of hospitalisation expenses for patients undergoing cardiac interventional surgery in Guangzhou found that inpatient expenses for those with medical insurance were significantly higher than those without insurance. Fang et al. also found that the higher coverage of commercial insurance was associated with higher medical costs. One explanation could be that middle and high income groups are more likely to buy health insurance and are more willing to pay for the best treatments and medicines. The true medical cost of CVD in this study might be potentially underestimated if social/private insurances increase their coverage, including reimbursement rates and caps, which could encourage people to increase their use of healthcare services – both in terms of frequency and quality. Therefore, insurance providers should be careful in designing their products to prevent excessive use of the coverage, which could result in higher costs and waste.

Besides drug costs, the long-term costs include the significant cost of care after severe CVDs events. Disability income insurance and long term care (LTC) insurance could provide protection for patients and financial stability.

Besides drug costs, the long-term costs include the significant cost of care after severe CVDs events, such as stroke. Social insurance schemes are more concentrated on the coverage of inpatient costs and less on the costs for care after a patient is discharged from hospital. More than one-third of stroke survivors have some degree of disability and need assistance for daily living. Because of the 4-2-1 family structure, more and more disabled elderly patients, after CVDs events, are seeking care services from caregivers instead of family members. The monthly cost of full-time caregivers could be around RMB 2000–5000 (USD 300–800) for big cities like Beijing and Shanghai. However, in 2014, the average retirement income in Beijing is only about RMB 3000 (USD 500). As the demand and costs of caregiving service increases, patients and their families will face heavier financial burdens.

The indirect cost comes from the loss of income for both patients and their family members. Huffman et al. found that there is a significant decrease in individual income after CVD hospitalisation for both individuals and households. Disability income insurance and long term care (LTC) insurance could provide protection for patients and financial stability.
The medical costs of cardiovascular diseases consist of both acute hospital expenses and long-term healthcare expenditures. Among those, the cost associated with medicine is the major cost driver. The non-medical costs associated with CVD events, such as loss of income, also contribute to the financial distress of patients. The CVD inpatient medical cost represents a larger percentage of total annual expenditure for rural residents compared to urban residents. Health spending as a portion of total annual expenditure varies by geographic location due to the disparities in social insurance coverage, economic development and quality of healthcare.

Studies indicated that financial protection for CVD patients is insufficient in China. The lack of protection affects low income groups the most. Nearly half of the inpatient costs were paid out-of-pocket by low income groups. About one-fourth of patients self-discharged due to financial stress as a result of high medical costs and the lack of insurance protection. The reimbursement cap on inpatient costs may have contributed to the relatively high out-of-pocket expenditures for CVD. While the reform of the essential medicines system has reduced high out-of-pocket medicine spending, a gap still exists. Reimbursement rates vary across regions due to differentiated healthcare needs. Since the in-/out-patient medical costs are expected to continue increasing in the future, there is a growing need to fill the gap between medical cost and the financial protection available currently, particularly for households with chronic diseases like CVD.

CVD insurance policies could supplement the national insurance coverage to cover the out-of-pocket medical expenses such as deductible, co-payment and any amount exceeding the reimbursement caps. In addition, CVD insurance products in China could expand to include long-term care and non-medical costs such as physical therapy, nursing care, transportation & lodging and lost wages. As China is making progress to open its insurance markets to commercial insurers, more and more life and health insurance products are expected to be sold to individuals as additional protection to supplement the national social insurance system. Findings from this paper could support the design and pricing of CVD-related medical insurance in China.
References

20. Swiss Re Asia Medical Survey 2014
Closing the financial gap for cardiovascular disease in China

22. Pricing and Reimbursement for High Value Therapies in China
   http://www.bio.org/sites/default/files/BD_Newsletter_issue8_BCIC_EN_20131003.html


under Cardiac Interventional Surgery with or without Urban Medical

25. Fang K, Shia B, Ma S (2012). Health Insurance Coverage and Impact:


27. http://money.163.com/14/0426/13/9QOU6OTR00253B0H.html

About the authors

Xiaojie Wang
Xiaojie Wang joined Swiss Re’s Population Risk and Data Analytics R&D team in March 2013 as an Actuarial Analyst. Before, Wang worked at New Era Life Insurance Company as an Actuarial Analyst for more than two years, mainly on life valuation. She became an Associate of the Society of Actuaries (ASA) in 2012. In 2011, she obtained her Master’s degree in mathematics with a focus on actuarial science from the University of Texas at Austin.

David Lu
Dr David Lu joined Swiss Re in January 2013 as Deputy Regional Chief Medical Officer for Asia. He is mainly responsible for the Great China area including China, Hong Kong and Taiwan. Before joining Swiss Re, he gained 10 years of working experience at a UK-based international medical insurance company as Assistant General Manager of Medical and Underwriting of Hong Kong. Besides his underwriting role, he was also responsible for leading clinical governance and total health management to ensure access to quality and appropriate care as well as to help people live longer, healthier, happier lives. Dr Lu received his Bachelor’s degree in medicine at The School of Medicine, Beijing University in 1986 and was employed by the First Hospital of Beijing University as an orthopaedic surgeon. In 1992, he was sponsored by the Shionogi Cell Science Research Foundation to conduct research on minimal invasive spinal surgery in Japan, under the supervision of Professor Kiyoshi Kaneda, the world-renowned spine surgeon and scientist. Dr Lu obtained his Doctoral degree in medical science in 1997 from Hokkaido University, Sapporo, Japan and a certificate of advanced clinical training for spinal surgery from the Japanese Ministry of Health.

Hueyfang Chen
Hueyfang Chen graduated with a Bachelor of Science in actuarial science and finance from the University of Illinois at Urbana-Champaign. In 2007, she became a Fellow of the Society of Actuaries (FSA) and a Chartered Enterprise Risk Analyst (CERA). For about 3 years, Chen worked at Towers Watson (previously Towers Perrin) in Life Actuarial Consulting before joining Swiss Re in 2008 where she is currently Head of Life & Health R&D Modelling.
Lost life expectancy due to air pollution in China

Douglas W. Dockery, C. Arden Pope III

Smog in Beijing and other Chinese cities has caused pollution to reach unprecedented levels. It is impossible to measure the health costs or loss of life due to air pollution with absolute accuracy or certainty. Nonetheless, data suggests that poor air quality imposes a significant health burden on the urban population. When the Prime Minister quipped that living in Beijing would shorten his life by 5 years, he succinctly captured the risk air pollution poses to Chinese city dwellers. Chinese authorities are now looking at ways to address air pollution and other environmental concerns, both to manage public health costs and to lessen the impact on economic growth.

Introduction

Air quality in the United States and Europe has substantially improved over the last couple of decades, and cleaner air has contributed to increased life expectancy. However, in many countries in the developing world, air pollution control has been sacrificed in the name of economic development.

The severe and deteriorating air pollution situation in China is a case in point. The high particulate air pollution readings in Beijing have been documented and reported on the web by the US Embassy. The Chinese government has begun publishing real time measurements of air quality in most cities. There is increasing concern that poor air quality is not only harming the people, but may also be harming economic growth in China.

Winter air pollution events in the north of China are common, and the hazard is well recognised. "If I work in your Beijing, I would shorten my life by at least five years," Zhu Rongji told city officials when he was prime minister in 1999. However, the government is just beginning to try and control or at least mitigate these air pollution events. In October 2013, a particularly severe air pollution episode in the northern city of Harbin was reported around the world. In blogs, people reported not being able to see their hands in front of their faces or other people. The Harbin government reported an air quality index (AQI) score of 500, the highest possible reading, and concentrations of PM2.5 – ie fine particulate matter that are 2.5 microns or smaller in diameter and especially harmful to health – of 1 000 micrograms per cubic meter (mg/m³).

These anecdotal reports and quantitative measurements from Harbin (Figure 1) are remarkably similar to those from London during the 1952 Great Smog (Figure 2). Health data from Harbin have not been reported, but in London 4 000 excess deaths were attributed to this event. Recent analyses have suggested that the true number of excess deaths could be 12 000.

This Harbin episode coincided with the mandated start of heating of the homes and offices. The policy of providing free coal for heating in the north has been associated with persistently high winter particulate air pollution levels in northern cities. A recent analysis evaluated the effect of this policy. Outdoor ambient concentrations of particulate air pollution (Total Suspended Particulates) were found to be 55% higher and life expectancies 5½ years shorter in the north. Deaths due to cardiorespiratory causes were notably higher.
Outdoor air pollution in China was estimated to contribute to 1.2 million premature deaths and 25 million healthy years of life lost.

Figure 1: Estimated 2005 annual average PM$_{2.5}$ concentrations (μg/m$^3$).

This paper seeks to provide estimates on loss of life expectancy due to exposure to air pollution.

In December 2012, the Global Burden of Disease analyses were published in The Lancet. As part of that effort, average 2005 fine particle (PM$_{2.5}$) air pollution was estimated across the world (Refer to Figure 1). Outdoor air pollution in China was estimated to contribute to 1.2 million premature deaths and 25 million healthy years of life lost. Outdoor air pollution was ranked as the fourth leading risk for loss of life expectancy in China; indoor air pollution from burning solid fuels for heating and cooking was the fifth leading cause.

These huge numbers of excess deaths and total years of life expectancy are compelling, but fail to communicate the risk to an individual of life-long exposure to extremely high air pollution, or the risk to visitors or temporary residents. The objective of this commentary is to provide useful, comparable effect estimates on loss of life expectancy under various exposure scenarios for exposure to air pollution and, for comparison, to cigarette smoke, a common, well studied risk.
Methods

Our estimates of survival curves and life expectancy are derived using standard lifetable techniques and are calculated using 2008 age-specific death rates for the total population of the United States. The counterfactual, baseline, life expectancy for non-smokers is calculated adjusting the rates for ages 18 years and older to 80% of rates from the total population. This provides hypothetical population-based mortality rates and estimates of life expectancy for a contemporary, healthy, non-smoking population. We estimated life expectancy for various exposure scenarios by multiplying the baseline age-specific death rates by the relative risks for each of these scenarios.

Excess risk estimates for the various air pollution exposure scenarios are based on recent literature reviews. Specifically, excess risk from exposure to air pollution in a mildly polluted city (15 μg/m^3 mean PM$_{2.5}$), a moderately polluted city (25 μg/m^3 mean PM$_{2.5}$), and a highly polluted city (55 μg/m^3 mean PM$_{2.5}$) relative to a very clean city (5 μg/m^3 mean PM$_{2.5}$) are estimated to be 7%, 14%, and 30%, respectively. The excess risk estimates for a highly polluted city may somewhat underestimate the effects of air pollution of Beijing for two reasons. First, average PM$_{2.5}$ concentrations in Beijing are reported to be 58 μg/m^3 in 2005 and have been getting worse. Second, we are using more conservative risk estimates than would be obtained by linear extrapolations from US cohort studies because of recent evidence that the exposure-response function flattens out at higher levels of exposure.

Results and discussion

Figure 2 illustrates differences in the life-table derived survival curves and life expectancy for the different exposure stylised scenarios. Cigarette smoking significantly adversely alters the survival curves. A lifetime of exposure to ambient air pollution in a highly polluted city has a similar, but less dramatic impact on the survival curves. Lifetime exposure to second-hand smoke (SHS) has a somewhat smaller, but similar effect (not shown in Figure 2).

Excess risk estimates for air pollution scenarios were based on literature reviews.
Lost life expectancy due to air pollution in China

Table 1 presents the estimated years of life expectancy and the estimated reduction in estimated life expectancy, relative to the baseline. Long-term active smoking clearly has a substantial impact on life expectancy ranging from 4½ to 12½ years lost, depending on the level of smoking. The loss of life expectancy is substantially reduced for smokers that quit smoking. How much loss of life expectancy will occur depends on various factors including, level of smoking, the age when an individual began and stopped smoking, and the lagged or residual excess risk from the smoking upon cessation. For an ex-smoker who smoked from age 18–40, life expectancy would be almost two years less than if he/she had never smoked, but nearly 6 years longer than if he/she had continued smoking.

Table 1:
Life table derived estimates of reduced life expectancy from different exposures to cigarette smoke and ambient fine particulate matter air pollution

<table>
<thead>
<tr>
<th>Baseline life expectancy (LE)</th>
<th>Years LE</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline LE for never smoker at birth</td>
<td>80.6</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long-term exposures to active cigarette smoking</th>
<th>Years LE</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker, heavy, since age 18 (add 200% excess risk since age 18)</td>
<td>68.1</td>
<td>12.5</td>
<td>4,571</td>
</tr>
<tr>
<td>Smoker, moderate, since age 18 (add 100% excess risk since age 18)</td>
<td>72.8</td>
<td>7.8</td>
<td>2,851</td>
</tr>
<tr>
<td>Smoker, light, since age 18 (add 50% excess risk since age 18)</td>
<td>76.1</td>
<td>4.5</td>
<td>1,653</td>
</tr>
<tr>
<td>Ex-smoker, moderate smoker from age 18-40 (add 100% excess risk from age 18-40, 50% at age 41, 25% age 42, 10% thereafter)</td>
<td>78.7</td>
<td>1.9</td>
<td>701</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long-term exposure to second hand cigarette smoke</th>
<th>Years LE</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live/Work with smoker 18+ (add 25% excess risk from age 18)</td>
<td>78.1</td>
<td>2.5</td>
<td>903</td>
</tr>
<tr>
<td>Live/Work with smoker 18–65 (add 25% excess risk from age 18–65)</td>
<td>79.6</td>
<td>1.0</td>
<td>352</td>
</tr>
<tr>
<td>Live with smoker as child with no lagged/residual risk (add 25% excess risk from age 0–18)</td>
<td>80.4</td>
<td>0.2</td>
<td>74</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Long-term exposures to air pollution</th>
<th>Years LE</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifetime in mildly polluted city (add 7% excess risk from birth)</td>
<td>79.8</td>
<td>0.8</td>
<td>292</td>
</tr>
<tr>
<td>Lifetime in moderately polluted city (add 14% excess risk from birth)</td>
<td>79.0</td>
<td>1.6</td>
<td>569</td>
</tr>
</tbody>
</table>

Source: author

Living with a smoker throughout adult life could reduce life expectancy by 2.5 years.

Life-time exposure to ambient air pollution, comparable to that found in Beijing, may reduce life expectancy by approximately three years.

As can be seen in Table 1, living with a smoker throughout adult life could reduce life expectancy by up to 2½ years. On the other hand, working with a smoker between 18 and 65 years was estimated to reduce life expectancy by only 1 year, assuming the increased risk does not persist once exposure stops. Because of the relatively low baseline risks of mortality for children, exposure to SHS as a child results in a reduction in life expectancy of only about 74 days. If, however, the increased risks of childhood exposure to SHS persist, the reduction in life expectancy may be substantially higher.

The estimated reduction in life expectancy from a lifetime of exposure to ambient air pollution clearly depends on the level of pollution (Table 1). For example, lifetime exposure to air pollution in a mildly polluted city (16 μg/m³ mean PM$_{2.5}$) or a moderately polluted city (25 μg/m³ mean PM$_{2.5}$) relative to a clean city (5 μg/m³ mean PM$_{2.5}$) results in an estimate of 0.8 and 1.6 years reduction in life expectancy. Life-time exposure to ambient air pollution, in a highly polluted city (comparable to Beijing, China) may result in an estimated loss of life expectancy of approximately 3 years.
Thus a lifetime of exposure to air pollution either from outdoor air pollution, indoor air pollution from SHS, or personal smoking can lead to years of lost life expectancy. Living in a highly polluted city has estimated effects comparable to or even greater than that from living with a smoker. Smoking, however, is a personal choice and only a fraction of the population engages in this voluntary exposure. On the other hand, breathing is not. The entire population is exposed to ambient air pollution. The net effect on population of a 3.1 year reduction in life expectancy across everyone breathing ambient air pollution is much larger than a 7.8 year reduction only among those smoking.

It is useful to compare these risks in terms of the incremental effect of each year of exposure. This helps us appreciate the effect of potential changes in exposures or behaviours. It also provides insights into the comparative risk for a worker or student who temporarily moves to such an environment.

To illustrate, Table 2 presents the estimated reduction in life expectancy for a 50-year old non-smoker who spends one year in various modelled cites with mild, moderate and high PM$_{2.5}$ air pollution. Because the incremental reductions in estimated life expectancy for each year of exposure are small, we report these as days lost per year. One year of living in an elevated air pollution environment could result in as much as a few days to a few weeks of shorter life expectancy per year, depending on the levels of pollution and age at time of exposure. If the increased risks from a one year exposure were to persist, even only in part, the reduction in life expectancy would be larger. Because the baseline risk goes up with age, the impact of each year of exposure to high pollution on life expectancy is much larger at age 65 (21 days lost life expectancy) than it is at age 50. Likewise, the impact on lost life expectancy is less at age 35 years (5 days).

Table 2:
Estimates of reduced life expectancy for 1 year exposures to cigarette smoke and ambient fine particulate matter air pollution at 50 years of age

<table>
<thead>
<tr>
<th>One-year exposure at age 50 with various PM$_{2.5}$ pollution levels</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Living in mildly polluted city (add 7% excess risk)</td>
<td>.008</td>
<td>3</td>
</tr>
<tr>
<td>Living in moderately polluted city (add 14% excess risk)</td>
<td>.015</td>
<td>6</td>
</tr>
<tr>
<td>Living in highly polluted city (add 30% excess risk)</td>
<td>0.032</td>
<td>12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>One-year exposure at age 50 with various smoking exposures</th>
<th>Reduced years LE</th>
<th>Reduced days LE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoker, heavy (add 200% excess risk)</td>
<td>2.16</td>
<td>79</td>
</tr>
<tr>
<td>Smoker, moderate (add 100% excess risk)</td>
<td>1.08</td>
<td>39</td>
</tr>
<tr>
<td>Smoker, light (add 50% excess risk)</td>
<td>.054</td>
<td>20</td>
</tr>
<tr>
<td>Live/Work with smoker (add 25% excess risk)</td>
<td>.027</td>
<td>10</td>
</tr>
</tbody>
</table>

Source: author

The estimates provided are for the population life expectancy and do not refer to how much any individual’s life is shortened by one year of exposure to pollution.

What does this mean for the individual?

These estimates are for the population life expectancy and do not provide specific estimates how much any individual’s life is shortened by one year of exposure in a polluted city. In fact, in this modelling exercise, we assume that if the person survives this experience, they would go on with the normal expectation of death with no increased residual risk. Evidence from smoking cessation studies suggests that risk of fatal cardiovascular events (ischemic heart or cerebrovascular), the primary cause of death from these exposures, begins returning to near normal within a few weeks/months of cessation of smoking and is only somewhat elevated after a few years. For respiratory conditions, air pollution exposure can contribute to accelerated, irreversible loss of lung capacity. It may take months to years to return to normal risk, and indeed there may be permanent but small elevated risk.
For an individual, the implication of these results is not that their life is measurably shortened. Rather these estimates reflect the increased probability of death each year. Again to illustrate, among one thousand (1000) non-smoking 50 year olds, we would expect 3½ to die within a year. If all of them smoked, we would expect an additional 3½ to die (ie only a fraction of them would be expected to take up this behaviour). Alternatively, if the non-smokers experience PM\textsubscript{2.5} air pollution of approximately 55 mg/m\textsuperscript{3} for a year, we would expect one additional death (ie in this case everyone is at risk).

These individuals would most likely die from acute events such as a myocardial infarction, stroke, asthma attack or traffic accident. It is assumed that once the air pollution exposure is removed – eg by moving to a cleaner city – the excess risk of dying returns to normal.

Living/working in a moderately polluted city has comparable effects on life expectancy as living with a smoker or working in an environment with substantial second-hand smoke.

Can individuals take actions to protect themselves, other than leaving?

The most effective strategy is to reduce your own baseline risk of cardiorespiratory death\textsuperscript{12}. Air pollution affects those with pre-existing chronic cardiovascular conditions the most. Masks and other breathing protection are not very effective in preventing individuals from breathing in or limiting exposure to ambient particles. Air pollution affects those with pre-existing chronic cardiovascular conditions. Long-term strategies to reduce risk of cardiorespiratory disease have the added benefit of reducing the likelihood of death due to air pollution.

Masks are not very effective in preventing individuals from breathing in or limiting exposure to ambient particles. Office and home air conditioning has some limited benefit in reducing exposures to ambient outdoor air pollution. Indeed gaseous pollutants (eg sulfur dioxide, ozone, nitrogen oxides and other water soluble gases) are readily removed by air conditioning. However, the normal filters in air conditioners are only modestly helpful in removing inhalable, airborne particles. Office and home filters can be helpful if specifically designed for removal of small particles, eg HEPA filters. However, targeted filtering of inhalable particles is difficult, expensive and requires regular cleaning and maintenance. Thus, the preferred approach is cleaning up the ambient outdoor air.

Summary and conclusions

From these calculations, it becomes apparent that outdoor particulate air pollution is having a substantial effect on life expectancy in much of the developing world. As George Box reminded us “All models are wrong, but some are useful\textsuperscript{13}.” This model of life expectancy valuing the effects of air pollution and cigarette smoking in the currency of days of lost life expectancy is simplistic, ignores many nuances in the actuarial data, and in that sense is clearly wrong. However, this approach helps us understand the comparative impact of air pollution relative to other known risk factors.

It is impossible to measure the total health costs or loss of life due to air pollution in China, or elsewhere with absolute accuracy or certainty. However, when the Prime Minister quipped that living in Beijing would shorten his life by 5 years, he succinctly captured the reality that air pollution imposes a substantial health burden on the population in China.

Most countries have seen a dramatic improvement in life expectancy over the past 50 years that appears to be at least correlated with economic development. Failure to address air pollution and other environmental concerns, however, is now being recognised as a significant public health burden and a potential impediment to economic growth.
References


About the authors

Douglas W. Dockery
Douglas W. Dockery is Professor of Environmental Epidemiology in the Department of Environmental Health at the Harvard School of Public Health. He is internationally known for his innovative work in environmental epidemiology, particularly in understanding the relationship between air pollution and respiratory and cardiovascular mortality and morbidity. He was one of the principal investigators of the landmark Six Cities Study of Air Pollution and Health, which showed that people living in communities with higher fine particulate air pollution had shorter life expectancies. The International Society for Environmental Epidemiology honoured him with its first award for Outstanding Contributions to Environmental Epidemiology in 1999 and the first Best Paper in Environmental Epidemiology Award in 2010.

C. Arden Pope III
C. Arden Pope III is Mary Lou Fulton Professor of Economics in the Department of Economics at Brigham Young University in Provo, Utah. Pope has conducted or collaborated on various key studies of human health effects of short and long-term air pollution exposure. He has played prominent roles in reviewing and interpreting this literature and is a widely cited and recognised expert on the health effects of air pollution. He has been the recipient of various honours and awards, including the Thomas T. Mercer Joint Prize from the American Association for Aerosol Research and the International Society for Aerosols in Medicine (2001) and is an Honorary Fellow of the American College of Chest Physicians (FCCP Hon, 2008).
Overview of health risk factors in Brazil

Marcia C. Castro

Brazil has made significant progress in reducing infectious diseases, although problems still persist. Currently non-communicable diseases (NCDs) represent the largest mortality and morbidity burden in the country. This situation may become more critical as the population ages and the prevalence for being overweight and obese increases. Brazil has a historically good record of facing health challenges through large scale campaigns. It most recently became the global leader in tobacco control, despite being among the top 5 producers of tobacco in the world. This article discusses historical and current pattern of mortality, morbidity and associated risk factors in Brazil, particularly when faced with structural demographic change. It also discusses government programmes, such as the Family Health Strategy and the Strategic Action Plan to tackle NCDs.

Health campaigns in Brazil: A brief history

Several historical events related to public health in Brazil since the Republic era, ranging from discovery of new diseases, to novel control methods of malaria, to large scale campaigns, played an important role in the past and to some extent set the context for what we observe now in the country. An important event in creating a momentum for change was a speech delivered by a physician named Miguel Pereira in 1916 at the Medical School in Rio de Janeiro. While referring to expeditions that assessed the health conditions of rural areas in the North and Northeast regions, he stated that rural Brazil was an enormous hospital.

Poor health conditions of the poor and rural populations were seen as an obstacle to economic development. Sanitation movements, which brought together physicians, scientists, intellectuals and politicians, resulted in major reforms of the sanitary services in the country. Important milestones included the start of the Pro-Sanitation Movement in 1916, as well as the creation of the National Department of Public Health in 1920 and the Ministry of Education and Public Health Affairs in 1930.

Large scale (and mostly vertical) campaigns were launched to address specific diseases such as yellow fever, bubonic plague, smallpox and malaria. This model of intervention gained momentum, and many of these campaigns received support from the Rockefeller Foundation. There are campaigns still present in Brazil, such as the National Immunization Day against Poliomyelitis.

Demographic transition

Crucial to the understanding of current health risk factors in Brazil is the demographic transition that brought about major changes to the structure of the population, coupled with patterns of economic growth and social changes that have been observed since the mid-20th century.

Demographic changes in Brazil have had an impact on current health risk factors.

At one time, poor health conditions were seen as an obstacle to economic development.

A series of historical events including a 1916 speech by Miguel Pereira, a leading physician, shaped the discourse on public health in Brazil.

Campaigns were launched to combat specific diseases such as yellow fever, bubonic plague, smallpox and malaria.

Brazil’s population grew rapidly between 1940 and 1970. However, the total fertility rate from dropped from 6.3 in 1960 to 1.9 in 2010.

Brazil experienced high population growth between 1940 and 1960, an average of 2.8% per year. After a similar growth between 1960 and 1970, the growth started to decline in the 1970s (2.5%), reaching an average of 1.64% per year during 1991 and 2000, and 1.17% between 2000–2010. The total fertility rate (TFR) remained at high and relatively constant levels between 1940 and 1960. A modest and slow decline since the early 1900s and small oscillations in fertility in the 1950s and 1960s have been reported. Nevertheless, important demographic transformations started in the mid-1960s. In four decades, the TFR experienced a dramatic decline: from 6.3 in 1960 to 2.3 in 2000, and the 2010 Population Census indicated a TFR of 1.9. This decline occurred in all regions and across different socioeconomic groups.
Overview of health risk factors in Brazil

Life expectancy has steadily increased since 1940 and by 2012 was 74.6 for males and 78.3 for females.

Regarding mortality, in the 1940s life expectancy in Brazil was below 50 years. By 2012, the number increased to 74.6 (71 for males and 78.3 for females). Most of the gains in life expectancy were a direct result of the decline in infant mortality (IMR). Brazil had an IMR of 162 per 1000 live births in 1930; between 1930 and 1970, IMR declined by 29.2%, and between 1970 and 2005, it fell 79.7%. According to the 2010 Population Census, IMR was 15.6.

Due to changes in mortality and fertility, the median age of the population has increased.

As a result of these changes in mortality and fertility, the age structure of the population became older. In 1950, the median age of the population was 18, with 41.8% of the population concentrated in ages younger than 15, and 4.3% aged 60 or older. In 2010, the median age increased to 27, with 24.1% of the population younger than 15, and 10.8% aged 60 or older. In the wealthiest regions of the country (Southeast and South), the median age of the population is even higher at 32.

Brazil's population has become more urbanised since 1950 and now has better access to infrastructure.

In addition, it is worth highlighting that: (i) the population became more urbanised: from 36.2% in 1950 to 84.4% in 2010; and (ii) the population had better access to infrastructure. Access to electricity increased from 68.5% in 1980 to 99.5% in 2012; 25.8% of the population had access to sanitation in 1980 and 97.4% had access in 2012. In 1980, 47.5% had access to piped water, while in 2012 this figure increased to 84.3%.

National income has risen since the 1960s; however, economic inequality also increased.

National income increased between the 1960s and 1990s more than 3 times, accompanied by an augmentation of social disparities. Brazil became one of the most unequal countries worldwide – it ranked 2nd in income concentration in 1998, and in 1999, it was the country with the highest ratio between the average income of the 20% richest and the 20% poorest, above 30.

Since 2001, economic inequality has improved.

Since 2001, a steady decline in inequality has been observed, with the Gini Index decreasing from 57.1 in 2001 to 50.5 in 2012. This decline was observed in 80% of Brazilian municipalities.

Disease burden has changed. By 2007, nearly 75% of deaths were attributable to non-communicable diseases.

The pattern of disease burden in Brazil has also been changing, particularly since the 1950s. The proportion of total deaths due to infectious diseases decreased from almost 50% in 1930 to about 5% in 2007. In contrast, in 2007 approximately 72% of all deaths were attributable to non-communicable diseases (NCDs) including cardiovascular diseases (the main cause of death), chronic respiratory diseases, diabetes, cancer, and others, including renal diseases.

Infectious diseases are in decline, although the control of dengue and visceral leishmaniasis is still a challenge.

Regarding infectious diseases, Brazil observed important successes/partial successes, and some failures. Among the successes are: the control of vaccine-preventable diseases, the reduction in mortality by diarrhea, and the control of Chagas disease. Partial successes include the control of leprosy, schistosomiasis, malaria, hepatitis, HIV/AIDS and tuberculosis. Among the failures are the control of dengue and visceral leishmaniasis.

Mortality due to cardiovascular and chronic respiratory diseases is on the decline, but diabetes and hypertension have increased.

Mortality and morbidity for NCDs are greatest among the poor. Age-standardised mortality due to NCDs registered a 20% decline between 1996 and 2007, mostly for cardiovascular and chronic respiratory diseases. The decline was associated with reductions in smoking and expansion of primary health care. Indeed, standardised mortality rates for cardiovascular disease decreased from 287.3 per 100 000 people in 1980 to 161.9 in 2003 (the disease with the largest decline in the same period was stroke: from 95.2 to 52.6 per 100 000 people). However, diabetes and hypertension are increasing, as is the prevalence of overweight and obesity in the population.

Current situation regarding risk factors

In 2006, the Brazilian Ministry of Health established the annual Telephone-based Surveillance of Risk and Protective Factors for Chronic Diseases' (VIGITEL), comprising state capitals and the Federal District (about 54,000 interviews a year). It allows the analysis of risk and protective factors of NCDs found in the adult population (aged 18 years or older)27.

Brazil has made important progress towards reducing smoking: the prevalence of smoking in 2011 was 14.8%, a major decline from 34.8% in 1989 (as reported by the National Survey on Health and Nutrition (PNSN))25,28,29. This was achieved through several preventative legal actions began in 1996 (eg tax increases, use of picture warnings on cigarette packs, and bans/restrictions on advertising)30.

While a long time series on physical activity in Brazil is not available, data from VIGITEL shows that about 15% of the adult population engaged in at least 30 minutes of some type of physical activity for at least five days a week in 2010, with the most active being young and well educated males. About 14% were inactive, and 28.2% reported watching three hours or more of television a day31.

The nutritional transition in Brazil is of crucial importance and one of the greatest challenges ahead18, while the prevalence of child stunting declined, the prevalence of overweight and obesity has significantly and steadily increased in the recent past12,33. In 2011, the overweight incidence among adults was 48.5% (52% among men and 45% among women); in 1974–75, the overweight incidence was 18.6% among males34,35. The prevalence of obesity has increased from 11.4% in 2006 to 15.8% in 2011. This is also a concern among children aged 5–9: in 2008–9, 33.5% and 14.3% of these children were overweight and obese, respectively18.
The distribution of risk factors differs by social group; smoking, consumption of high fat meat and obesity are more common among the less educated.

Although major achievements in health have been observed, some challenges remain. Brazil implemented the Family Health Program in 1994 to improve access to primary health care.

To address the steady increase in the number of overweight and obese individuals and to cope with the rise in non-communicable diseases, the Ministry of Health launched the Strategic Action Plan.

The programme also stresses the importance of physical activity and increased fruit and vegetable consumption.

Brazil continues to make significant progress in reducing infectious diseases, but is still looking to reduce non-communicable diseases.

The distribution of risk and protective factors is not equal among social groups. Smoking, consumption of meat with visible fat, and obesity are more common among the less-educated, while physical activity during leisure time and the recommended consumption of fruits and vegetables (five portions a day, five or more times a week) are higher among the population with 12 or more years of schooling. In addition, the highest increase in the prevalence of being overweight was observed in the North and Northeast regions (the poorest), while the increase in the prevalence of obesity was higher in the South and Southeast (the wealthiest).29

Discussion

Brazil has gone through major demographic, economic and social changes, and the epidemiological transition is still ongoing. While major achievements on the health arena have been observed, important challenges remain. Regarding NCDs, for example, the number of deaths due to cardiovascular disease has increased since 1980, mainly a result of the changes in the age structure of the population that is becoming older (and thus more elderly are exposed to the risk of chronic diseases).26 The standardised mortality rates, however, have been declining, mainly a reflection of declines in smoking and improved access to basic health care.25

Regarding access to health care, the Family Health Program, implemented in 1994, aims to improve access to primary health care, utilising a community-based approach for local care provision. Health care services are provided by a team comprised of at least one physician, one nurse, one nurse assistant, and up to six community health workers; some teams may also include a dentist and two assistants. Each team is responsible to provide care for up to 1000 families (or approximately 4500 people) in a determined geographical area.37 As of December 2013, 64.7% of the population was reached by community health agents, and 56.4% covered by family health teams (with marked regional differences).

Currently, one of the most pressing challenges regarding NDCs is the significant and steady increase in the overweight and obese population (children, adolescents and adults). To address that challenge and others, in 2011 the Brazilian Ministry of Health launched the Strategic Action Plan to tackle NCDs in the country. The Plan aims at preparing Brazil to cope with and restrain NCDs in the next 10 years. It addresses four main groups of diseases (cardiovascular, cancer, chronic respiratory, and diabetes) and their shared modifiable risk factors (smoking, alcohol abuse, physical inactivity, unhealthy diet, and obesity). It describes guidelines and measures to be taken concerning: a) surveillance, information, evaluation, and monitoring; b) health promotion; and c) comprehensive care.29

The suggested national goals of the programme are to: reduce premature mortality rate (< 70 years old) caused by NCDs at 2% a year; reduce prevalence of obesity among children; reduce prevalence of obesity among adolescents; restrain obesity among adults; reduce prevalence of alcohol abuse; increase leisure time physical activity levels; increase fruit and vegetable consumption; reduce the average salt consumption; reduce prevalence of smoking; increase coverage for mammograms exams among 50 to 69-year-old women; increase coverage for cervical cancer preventive exams among 25 to 64-year-old women; and treat 100% of women diagnosed with precursory lesions of cancer.

In summary, Brazil has made significant progress in reducing infectious diseases, although problems still persist. NCDs currently represent the largest mortality and morbidity burden in the country, which can become more critical considering the ageing population and the increasing number of overweight and obese individuals. The successful implementation of the Strategic Action Plan to tackle NCDs (described above) will be crucial in the years to come. Historically, Brazil has shown a good record of facing health challenges, and most recently became the world leader in tobacco control, despite being among the top 5 producers of tobacco in the world.30,38 The future is yet to be written.
References


Overview of health risk factors in Brazil


About the author

Marcia C. Castro
Marcia Castro is Associate Professor of Demography in the Department of Global Health and Population at the Harvard School of Public Health, and Associate Faculty of the Harvard University Center for the Environment. The core of her research focuses on the development and use of multidisciplinary approaches, combining data from different sources to identify the determinants of malaria transmission in different ecological settings, providing evidence for the improvement of current control policies, as well as the development of new ones.
Understanding the global risk of the tobacco epidemic and its trajectory in an emerging market nation

Hillel R. Alpert

The tobacco epidemic is a “chronic global risk” and may be the single most important risk to determine longevity and mortality in the 21st century. This report closely examines how Brazil has been confronting its tobacco problem and provides insight into the societal characteristics and external and internal influences that will determine the course of the epidemic in Brazil and other emerging market nations.

Introduction

Brazil is both the second largest producer and leading exporter of tobacco, and the second country to fully sign the Framework Convention on Tobacco Control, which sets forth multi-sectorial and trans-frontier actions to combat the epidemic worldwide. Brazil’s tobacco control efforts to date have decreased male and female smoking prevalence by 50%; however, the early age of smoking initiation and relatively high prevalence of smoking among women are still of major concern. Brazil’s recent ban on the use of menthol and other flavors in tobacco products may spearhead how product regulation decreases tobacco use by reducing product addictiveness, attractiveness and abuse potential. Future trends will depend on tobacco marketing and promotion on one hand, and public health policies on the other, and their influences on the societal acceptability versus denormalisation of smoking.

The global risk of smoking

The tobacco epidemic is clearly a “global risk” of catastrophic proportions with large-scale implications for mortality and longevity in nations. Meeting the World Economic Forum’s definition of a global risk, the tobacco problem is global in scope, has economic impact, cross-industry relevance, requires a multi-stakeholder approach, and is associated with uncertainty. Tobacco was responsible for an estimated 110 million deaths worldwide during the twentieth century and 500 billion dollars in yearly losses due to illnesses, decreased productivity and premature deaths. Its future trajectory depends on many competing variables and thus entails considerable uncertainty. Because the harms of tobacco use and the benefits of cessation are well-established, it is the single most preventable cause of death worldwide. However, if current trends continue, tobacco use will grow and result in approximately one billion deaths from diseases during the 21st century. In contrast to acute or “event-driven” global risks, tobacco use is a “chronic” risk whose future course will be determined by private and public sector activities and developments at the global, national and local community levels. Uncertainties regarding its future course may be diminished with insightful analyses based on a clear understanding of its nature, knowledge of the factors that either promote or mitigate tobacco use in nations, and the wisdom of experience.
Understanding the global risk of the tobacco epidemic and its trajectory in an emerging market nation

The nature of the tobacco epidemic

An estimated 1.2 billion persons in the world currently smoke, while nearly 80% of tobacco-attributable deaths occur in low and middle-income countries. In order to anticipate or predict the course of the epidemic in nations or globally, tobacco use must be understood as a societal phenomenon, with the key influences on individual smoker’s behaviour occurring at the social, community and population levels. The tobacco industry has long known this and set maintaining the social acceptability of smoking as a strategic goal and formed a working party in the 1970s to “improve the climate of social acceptability.” The result has been the creation of social norms that treat smoking behaviour as acceptable, desirable and sometimes even expected for a member of society.

Similarly, research in California and Massachusetts has demonstrated that population interventions, such as clean indoor air laws, advertising restrictions and counter-marketing, have been far more successful in decreasing smoking prevalence than are individual level interventions. Public health experts have noted that notwithstanding the significant role of cessation therapies, the use medications or cognition to fight a larger group behaviour does not appear to be effective in bringing about large-scale changes, whereas changing social norms is. This report closely examines how Brazil as an emerging market nation has been confronting its tobacco problem in order to illustrate and provide insight into the societal characteristics as well external and internal influences that may determine the course of the epidemic in similar nations and globally.

Risk mitigation

Collective experience from local, state and national efforts to curb the tobacco epidemic led to the first international public health treaty, the WHO Framework Convention on Tobacco Control (FCTC), which was negotiated under the auspices of the WHO in 192 countries. The FCTC sets forth multi-sectorial and trans-frontier actions to combat the epidemic worldwide. It obliges parties to implement a variety of tobacco control measures, which include both tobacco product supply and demand reduction strategies. Each of the strategies is intended to have a direct effect on reducing tobacco use. For example, increasing cigarette pricing through taxation has been a highly effective intervention in many places for reducing the demand for cigarettes, especially among young people and persons from lower income brackets. Studies by the World Bank and others have showed that increases in taxes and prices have reduced per capita cigarette consumption in Brazil and other nations. Further effective measures include protecting the public from exposure to tobacco smoke; requiring tobacco product disclosures; regulating tobacco product packaging and labelling; restricting tobacco advertising, promotion and sponsorship; regulating the contents of tobacco products; and advancing public education, communication, training and awareness programmes. Over and beyond the effects of the individual policies, these measures have a collective, synergistic effect to socially denormalise smoking.

Smoking prevalence has decreased in nations that have adopted and successfully implemented the FCTC tobacco control policies. Yet, declines in prevalence have been limited as a result of continued tobacco industry marketing and promotion activities, the addictive nature of the product, and enduring social acceptance, even in nations where substantial progress has been made. Of the strategies available, tobacco product regulation has been used relatively little to date, but could potentially have far-reaching effects on smoking. Although some nations have set limits on tar levels and banned the use of misleading “lights” descriptors on packaging and in advertising, not much evidence exists to show significant effects on smoking prevalence as a result of these measures. Possible reasons are that low-tar cigarettes are no less harmful or addictive than other cigarettes, and “lights” descriptor bans appear to have been circumvented by substitution of alternative, color-coded descriptors that are recognised by consumers. The design and characteristics of tobacco products could be regulated in numerous ways, at least some of which could have significant effects on use by reducing product addictiveness and abuse potential.
The U.S. Food and Drug Administration (FDA) has been authorised by the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009 to set standards for tobacco product design, contents, and constituents; including banning the use of menthol and other flavors and additives that affect the appeal, attractiveness, and abuse potential of products particularly to youth, women and other potentially susceptible persons; as well as to set other product regulations. The FSPTCA provides a population-based set of criteria for the FDA to use in determining whether a tobacco product or design feature is “appropriate for the protection of the public health”. These include an assessment of the “increased or decreased likelihood that existing users of tobacco products will stop using such products; and the increased or decreased likelihood that those who do not use tobacco products will start using such products.” Once the FDA enacts its authority, the US experience with product regulation should be instructive to other nations in the future. In the meantime, Brazil has already recently implemented some tobacco product regulations whose results will be of interest to other emerging market nations.

Tobacco control in an emerging market nation

Brazil is ironically the second largest producer and leading exporter of tobacco, as well as the second country to fully sign the FCTC. It now has one of the strictest tobacco control legislations in the world. Brazil has implemented a societal, population-oriented approach to tobacco control since the Ministry of Health established the National Tobacco Control Program (NTCP) in 1989 through the Instituto Nacional de Cáncer. The programme’s initial dissemination approach was motivated by the need to reach opinion makers and form a critical mass with the aim of changing social acceptance of smoking. Smoking was seen at that time as a lifestyle choice and it had broad social acceptance in an environmental context of extensive advertising. The programme prioritised reaching three major community channels: schools, work environments and health units. The local media was included in this network as an important vehicle for increasing the population’s knowledge about the harms of smoking in order to reduce the social acceptance of smoking and motivate smokers to quit.

Tobacco control efforts began with large price increases followed by strong advertising restrictions and health warnings, and later by partial smoke-free air laws and increased availability of cessation programmes. Tobacco advertising is now banned, including mass media, internet and any other electronic means, as well as sponsorship at cultural or sporting events. The country has compulsory graphic warnings and insertions in packaging and advertising. Brazil’s states and municipalities have also widely adopted local laws banning smoking in closed public environments, including bars, restaurants, and public and private organisations. Strong public health campaigns continue to be conducted promoting adoption of healthy behaviours and lifestyles.
Since 1989, smoking prevalence among men and women has decreased nearly 50%.

Major accomplishments of Brazil’s tobacco control efforts include an almost 50% decrease among both male and female smoking prevalence since 1989. A policy simulation model called “Simsmoke”, which is designed to isolate the effect of tobacco policies from previous trends in smoking prevalence, estimated a 46% relative reduction in smoking prevalence from 1989 to 2010 associated with the policies implemented (Refer to Figure 1). Evidence suggests that the tobacco control efforts have also been effective in changing the social acceptability of smoking. Eighty-eight percent of both smokers and non-smokers reported to be against smoking in enclosed public places, and a similar percentage of the population is extremely supportive of even stronger than existing regulations for tobacco products.

Flavor additives have also been banned from cigarettes.

Brazil’s most recent tobacco product regulations may be groundbreaking. The ANVISA (Health Surveillance Agency) banned flavour additives to cigarettes, such as menthol, mint, clove, cinnamon, cocoa, vanilla, and others by March 2014. Ingredients such as these, when added to cigarettes, can make them more attractive to young people as well as mask the strong smell and flavour typical of the tobacco leaf. ANVISA also prohibited commercialisation, importation, and advertisement of any electronic smoking devices (ie e-cigarettes), while the sales and popularity of these devices have been growing rapidly in other countries.

The effectiveness of Brazil’s tobacco product regulations could be evaluated by comparing progress with a similar emerging market country such as Mexico, which does not have these regulations and could serve as a control. Aside from product regulation, Mexico’s tobacco control policies are comparable to those in Brazil with only a few differences. In Brazil, 100% smoke-free indoor air policies cover more areas than those of Mexico, more forms of advertising are banned, and larger, graphic, and more informational package warnings are required. Mexico, on the other hand, has: (1) some outdoor smoke-free policies, (2) penalties for not posting smoke-free signs, (3) prescribes steps for owners to take in order to stop persons from smoking, (4) bans cigarette sales through vending machines, and (5) explicitly bans false, misleading, or deceptive advertising, including the printing of tar, nicotine, and carbon monoxide levels on packages. The most prominent difference between the two countries’ tobacco control policies is the presence or absence of tobacco product regulations.
Despite the nation’s policy advances, Brazil continues to have a serious tobacco problem. While tobacco consumption has decreased over the last decades, the absolute number of tobacco users in the country is still very high (around 25 million among persons 15 years of age or older)\(^\text{12}\). Of continued and major concern are the early age of smoking initiation and the relatively high prevalence of smoking among women. Nine percent of boys and seven percent of girls between ages 14 and 18 are using tobacco\(^\text{15}\), and smoking is becoming increasingly popular among women.

Females now account for the majority (54%) of new smokers in the country\(^\text{15}\). As shown by Lopez et al, increases in female smoking prevalence in a country typically lags behind increases in male prevalence\(^\text{19}\) (Refer to Figure 2). Female smoking is often driven by: (1) “peer pressure”, (2) an association of smoking with being stronger and more mature, (3) images in relation to equal rights with men, (4) a view of smoking as an aid to weight loss (instead of eating) or weight gain often associated with quitting, and (5) increasing numbers of brands for female smokers\(^\text{15}\).

Targeted marketing plays a significant role. Following the development and marketing of menthol brands to young women, Japan experienced an upsurge in smoking among high school aged girls, particularly of menthol brands\(^\text{20}\).

Brazil still lacks an advertising ban on posters and panels, on the packaging itself, and at points-of-sale\(^\text{15}\). ANVISA proposed regulating advertising at retail points-of-sale and increasing visible warnings on packages, although these policies have not yet been adopted\(^\text{15}\). Brazil’s smoke-free laws are ignored in many establishments. Many people continue to smoke in stairwells of public places, such as theatres, hospitals, libraries and cinemas. Enforcement of the Brazilian Federal Tobacco Legislation forbidding the sale to children under 18 years of age remains lax\(^\text{15}\).

Increased application of 100% smoke-free policies combined with enforcement, visits by authorities and large fines to increase compliance, could further decrease the country’s smoking rate\(^\text{15}\).

While tobacco consumption has decreased, more than 25 million people in Brazil still smoke.

Smoking among women is becoming increasingly popular, with women accounting for the majority of new smokers.

Figure 2: Spread of smoking and smoking-related mortality within a country, over time

Advertising bans are not in place in Brazil.

Current and future of risk for smoking in Brazil

Source: Reproduced from Tobacco Control, Lopez, AD, Collishaw NE, Piha T (1994). A descriptive model of the cigarette epidemic in developed countries. 3. 242-247 with permission from BMJ Publishing Group Ltd.
Understanding the global risk of the tobacco epidemic and its trajectory in an emerging market nation

Cigarette spending in Brazil ranges from 4.8% to 7.0% of family expenditures, suggesting that existing price and tax policies are not optimal and that more could be done to make cigarette purchase less affordable\textsuperscript{12}. While monthly income or per capita income is an important indicator of overall purchasing power, a better indicator for the poorest sectors of society is the minimum wage divided by the average price of a cigarette package, which indicates the number of cigarette packages that can be purchased on a minimum wage\textsuperscript{12}. As of September 2008, a low-income smoker could buy 150 packages of cigarettes a month, while he or she could buy 83 in January 1996\textsuperscript{12}. The Ministry of Health is reportedly planning to implement a tax increase by 2015 to increase the price of cigarettes by 55%\textsuperscript{15}. These pricing policies could be significant as the purchasing power of the Brazilian population increases if the policies obtain an acceptable margin for the minimum wage/cigarette price ratio\textsuperscript{12}.

The future of smoking in Brazil will depend on the balance between efforts that promote versus mitigate the social acceptability of tobacco use. The Simsmoke model was also used to consider the potential effect of policies that had not yet been implemented. The model estimated that if tobacco control policies are strengthened in Brazil to be fully consistent with FCTC, the effect would be to decrease smoking prevalence by the year 2050 by up to 39%\textsuperscript{14}. The model does not consider directly the effect of income and purchasing power on smoking rates or feedback through social norms and attitudes, and peer and family behaviours\textsuperscript{14}. Brazil’s experience with its new tobacco product regulations may provide new empirical data to further refine the model’s predictions.

Globalisation and the potential use of “big data”

The “big data” approach may be another opportunity to gain insight into trends in smoking in emerging market nations. For example, analyses of a longitudinal, time-series global database of nations’ societal, human and economic development characteristics as well other data could reveal key factors that are associated with changing smoking prevalence. Such data are available from a number of comprehensive, global, country-specific sources, including: (a) the KOF Index of Globalization, which was developed at the KOF Swiss Economic Institute and measures three main dimensions of globalisation: economic, social, and political, annually for 207 countries over the period 1970–2011\textsuperscript{21, 22}; (b) detailed annual data pertaining to the politics, economy, risk, regulation and business environment of countries worldwide, which are available from the Economic Intelligence Unit\textsuperscript{23}; and (c) the WHO’s MPOWER reports, which include country level data pertaining to six evidence-based tobacco control measures for reducing tobacco use corresponding to the acronym\textsuperscript{24}. The measures are: (M) monitoring tobacco use and prevention policies; (P) protecting people from tobacco smoke; (O) offering help to quit tobacco use; (W) warning people about the dangers of tobacco; (E) enforcing bans on tobacco advertising, promotion and sponsorship; and (R) raising taxes on tobacco.

Preliminary analysis of these data found that predictors of a nation’s three year change in smoking prevalence differ by gender. Changing male smoking prevalence was predicted by a nation’s wealth, governance, education and economic globalisation; whereas changing female smoking prevalence was predicted by the single variable, social globalisation, as seen for example by an inverse relationship between change in smoking prevalence and internet use\textsuperscript{25}. Mexico’s social globalisation index was 33% higher than Brazil’s, while Mexico experienced an average 1.2% 3-year decline in female smoking prevalence during 1998–2012 compared to an average of 0.2% in Brazil\textsuperscript{25}. Possibly, the more that women in society use internet for telecommunications, social media and non-face-to-face interactions, the less time they might spend with others in-person and the
less exposure they may have to the social, physical, and psychological cues for smoking that encourage and reinforce tobacco use. The definitions and boundaries of communities may be changing in this era of globalisation, which may have important implications for the most common types of social influences on smoking behaviour. Models that are based on “big data” may be further refined by incorporating further data such as measures of promotional, or supply-side, influences. In addition, the path of the tobacco epidemic may be affected by factors having cross-border effects, including trade liberalisation, direct foreign investment, global marketing, transnational tobacco advertising, promotion and sponsorship, and the international movement of contraband and counterfeit cigarettes. Trade liberalisation may increase market competition, which may in turn lead to lower prices and other practices, such as increased marketing to stimulate demand26.

Relevant country-specific data is also being collected through the Global Tobacco Surveillance System (GTSS) organised by the WHO and the U.S. Centers for Disease Control and can be used to describe and analyse attitudes toward tobacco use, marketing and policies, in addition to smoking behaviours among youth and adults27. A Global Youth Tobacco Survey (GYTS) analysis of youth aged 13 to 15 years in 115 countries, primarily in the developing world, examined relationships between youth support for smoke-free-policies and smoking status, and exposure to secondhand smoke, controlling for demographic and environmental factors and country-level policy factors30. The majority of youth worldwide were found to support smoke-free policies in public places, many of whom are still living in areas still lacking these rules28. Youth attitudes data such as these provide a useful window into a society’s present and potentially changing social norms pertaining to smoking and might also reflect important future policy directions.

Conclusions

Tobacco use is a global risk of major importance and wide-ranging uncertainty. The risk of using tobacco will be influenced by local, national and global factors and by promotional versus mitigating factors. The future trends of tobacco use in low and middle-income emerging market nations such as Brazil and Mexico are likely to depend on the marketing and promotional activities on one hand, and on public health tobacco control policies on the other, and their respective abilities to influence the societal acceptability versus denormalisation of smoking. How effective traditional, evidence-based risk mitigating strategies will be in any nation depends on whether or not the measures are implemented in a comprehensive fashion and accompanied by effective enforcement. These policies where implemented have been embraced by smokers and non-smokers alike, even where smokers were initially reluctant or were opposed to them.

However, ongoing tobacco product innovation and development together with marketing and promotion continue to raise the bar and potential need for progressive tobacco control policies, such as lowering addictiveness through product regulation. Brazil’s experience in the coming years should be informative for regulatory authorities in other emerging market nations as well as the US and elsewhere. Recent “big data” approaches could be further augmented with data that gauge public opinion, especially the attitudes of youth and women as potential indicators of forthcoming trends. Increasingly large databases and computational resources are becoming available to track and project the future course of the tobacco epidemic, which may be the single most important risk to determine longevity and mortality in the 21st century.
Understanding the global risk of the tobacco epidemic and its trajectory in an emerging market nation

References

4. The Tobacco Institute (1980). Memorandum to executive committee: The Tobacco Institute Communications Committee presents this long-range plan to the executive committee. Bates number TI06431226-TI06431248.

About the author

Hillel R. Alpert
Dr Hillel R. Alpert is a public health scientist and expert with over 25 years of experience conducting applied policy and scientific research in the fields of tobacco control and epidemiology, population sciences, pharmacoepidemiology; environmental health and epidemiology, medical ethics; health care policy, quality and financing; clinical effectiveness and medical decision-making, regulatory science, and biomedicine. He earned a Bachelor of Science degree in Human Genetics at McGill University in 1975, a Master of Science degree in Health Policy and Management at Harvard School of Public Health in 1987, and Doctor of Science degree in Environmental Health at the Harvard School of Public Health in 2013. Dr Alpert received a post-doctoral fellowship from the Swiss Re/ Harvard School of Public Health SEARCH Program in which he examined the use of “big data” to model the risk for smoking and tobacco use in emerging market nations.
Chronic diseases in India: Burden and implications

K. Srinath Reddy, Sailesh Mohan

India currently faces the dual burden of communicable diseases and chronic non-communicable diseases (NCDs) such as cardiovascular disease (CVD), diabetes, cancer and chronic obstructive pulmonary disease (COPD). Success in controlling communicable diseases to some extent, as well as increased longevity and changes in people’s lifestyles driven by health transitions and economic progress, are contributing to the increase in NCDs. Increasing burden of NCDs has had not only obvious health implications, but also economic and developmental consequences. In this paper, we outline the major reasons for the increase in NCDs, the current and future risk factor and disease burdens, the responses so far and suggest key public health actions that can contribute to addressing and controlling NCDs effectively.

Why are NCDs increasing in India?

Substantial progress in societal development, health, nutrition and life expectancy occurred during the latter half of the 20th century. Consequently, deaths from communicable diseases have decreased, while those from NCDs have risen. This has been attributed to changes in demography (eg population ageing), epidemiology (eg the shift from communicable to non-communicable diseases) and nutrition (eg high caloric consumption and low physical activity levels). As a result, NCDs currently account for 53% of the total deaths and 44% of disability adjusted life years (DALYs) lost. Projections indicate a further increase to 67% of total deaths by 2030. CVD is the major contributor to this burden, attributable to 52% of NCD associated deaths and 29% of total deaths (Figure 1) 1, 2

Deaths from non-communicable diseases (NCDs) have risen due to changes in demography, epidemiology and nutrition.

Figure 1: Causes of death in India

![Figure 1: Causes of death in India](image)

Main Cause of Death in India, 2005

- 36.2% Communicable Diseases
- 29.0% Cardiovascular Diseases
- 16.0% Other Chronic Diseases
- 10.8% Injuries
- 8.0% Cancer

Main Cause of Death in India, Projected: 2030

- 35.9% Cardiovascular Diseases
- 21.0% Communicable Diseases
- 19.1% Other Chronic Diseases
- 12.1% Injuries
- 11.9% Cancer

Source: Adapted from Patel V et al (2011)1 and Mohan S et al (2011)2
What are the major risk factors?

Chief NCD risk factors are shown in Figure 2 and their contribution to the disease burden summarised below.

- High blood pressure
- Suboptimum blood glucose
- Low fruit and vegetable intake
- Tobacco use
- High cholesterol
- Indoor smoke from solid fuels
- Physical inactivity
- Overweight and obesity
- Alcohol use

Deaths (% of total)

Deaths (% of total)

Age <60 years ≥60 years

Source: Adapted from Patel V et al (2011)

Tobacco use

In India, tobacco is widely used in many forms (e.g., bidis, cigarettes, and electronic cigarettes). The country is the second-largest producer and the third-largest global consumer of tobacco. There are about 275 million tobacco users (Figure 3). Tobacco use is a leading preventable cause of premature, NCD-associated death and disability. Its use is increasing among India’s youth, women, and the poor. Almost a million deaths per year are attributed to tobacco use, with most of these deaths occurring among the poor and the economically productive group aged 30–69. By 2030, nearly 1.5 million deaths will occur annually from tobacco use. However, it not only entails health implications, but also significant economic costs. The conservative cost of treating three major tobacco-related NCDs (cancer, heart disease, and COPD) in 2002–2003 was estimated to be INR 308.3 billion (USD1=INR 60), which far exceeds the revenue added by tobacco taxes to the public exchequer.

There are 275 million tobacco users in India. By 2030, nearly 1.5 million deaths will occur annually due to tobacco use.
Diet, physical activity and alcohol use

Even though discernible changes in the per capita calorie consumption over the past few decades in India have not been reported, there have been noteworthy increases in edible oil and fat consumption, both in rural as well as urban areas. Oil intake had increased from 18 grams per person daily in 1990–1992 to 27 grams per person daily in 2003–2005, while fat intake increased from 41 grams to 52 grams per person daily during the same period. Aggregate consumption data also indicate an increasing trend in edible oil consumption, which has grown from 9.7 million tonnes in 2000–2001 to 14.3 million tonnes in 2007–2008, with a high proportion of unhealthy oils high in saturated and trans-fats that are linked to NCDs, particularly CVD.

Conversely, fruits and vegetable consumption, which provides protection against NCDs, is inadequate, particularly among the poor. Similarly, physical activity, another protective factor is at less than recommended levels, with 29% of the population being insufficiently active. Rapid and extensive urbanisation, increased mechanisation of work and adoption of sedentary lifestyles are attributable to reduced activity levels.

Dietary salt consumption, a key determinant of hypertension and associated CVD, is also very high, with the average intake ranging between 9-12 grams/day, far exceeding the World Health Organization (WHO) recommended intake of ≤ 5 grams/day.

Alcohol consumption, which results in not only adverse health outcomes, but also social implications, is increasing. It accounts for a significant proportion of neuropsychiatric disorders, fatal road traffic accidents and suicides. Use of alcohol is higher among the poor and less educated, but disconcertingly is also increasing among youth.

Cardiovascular disease

Currently, about 2.7 million people die of CVD annually in India. Roughly 30 million people suffer from coronary heart disease.

According to the International Diabetes Federation, there are about 65 million people with diabetes in India.

Diabetes mellitus

Type-2 diabetes mellitus has been rising rapidly. Until recently, India was often referred to as the ‘diabetes capital’ of the world. The most recent estimates from the International Diabetes Federation (IDF) suggest that there are about 65 million people with diabetes. This figure is projected to increase to 109 million by 2035.

Moreover, diabetes is an important risk factor for CVD; in persons with diabetes, CVD is the major cause of death and disability. Diabetes currently accounts for almost a million deaths annually.

Hypertension

Hypertension is the leading risk factor for CVD and accounts for nearly 10% of all deaths in India. Currently 20–40% of adults in urban areas and 12–17% of adults in rural areas suffer from it. The number of people with hypertension in India is projected to nearly double from 118 million in 2000 to 213 million by 2025. Moreover, nearly 40% adults have pre-hypertension, a precursor condition with high likelihood of converting into hypertension if left unaddressed.
Chronic diseases in India: Burden and implications

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is more common among men and has been attributed to the use of tobacco. The prevalence of the disease is also increasing among women due to indoor air pollution resulting from the use of solid fuels for cooking. The number of COPD patients is estimated to increase from 13 million in 1996 to 22 million by 2016, with many likely to require hospitalisation. This will lead to financial repercussions for both patients and the resource constrained healthcare system.

Cancer

About 800,000 new cases of cancer and 550,000 deaths occur in India each year. The most common cancers in men are those of the oral cavity, oesophagus and lung, while women suffer primarily from cervical, breast and ovarian cancers. Early diagnosis and treatment are often delayed, with more than 75% of cancer patients first surfacing and seeking care when they are already in the advanced stages of the disease. This vastly decreases the likelihood of positive treatment outcomes. Tobacco use is one of the leading risk factors, while alcohol use contributes to a substantial proportion of head, neck and stomach cancers.

Inadequate management and secondary prevention

Notwithstanding the availability of proven and effective prevention and treatment strategies for major NCDs like hypertension and diabetes, their management vis-a-vis detection and control rates are abysmally low. There is a huge gap between detection and adequate treatment: less than half of those who have hypertension or diabetes are actually detected, less than half of those detected receive appropriate treatment and less than half of those receiving treatment have their blood pressure or blood sugar treated to recommended targets (“The rule of halves”). In addition to poor control rates, of considerable concern is the fact that once hypertension-related CVD occurs, the use of proven, inexpensive evidence-based secondary prevention therapies is also very low in primary and secondary care, leading to a large and escalating burden of avoidable and premature mortality. A recent global study indicated that up to 80% of individuals were not on proven and effective life-saving drug treatment after a stroke or heart attack. This results in avoidable complications, increased healthcare costs, poor quality of life, premature disability and death.

Economic impact of NCDs

NCDs and risk factors entail huge costs not only to individuals, but also to the national economy. Most people suffering from NCDs incur out-of-pocket expenses for their healthcare costs. Medicines account for up to 45% of this expenditure. In 2004, the annual income loss among working adults due to NCDs was INR 251 billion (USD 4bn).

In 2010, the annual median direct cost per diabetic patient was reported to be USD 525, and the annual total cost of diabetes care in India was estimated to be USD 32 billion. During 2005–2015, the projected income loss due to CVD and diabetes alone is likely to exceed USD 237 billion. To obtain NCD care, individuals and families often resort to distress financing and pay vast amounts, which impoverish and ultimately drive people into poverty. Furthermore, families suffering from NCDs suffer income losses not only due to disease, but also due to care giving and premature death.

- Chronic obstructive pulmonary disease (COPD) is more common among men but on the rise among women.
- About 800,000 new cases of cancer and 550,000 deaths occur in India each year.
- There is a huge gap between detection and adequate treatment of NCDs. The use of proven, inexpensive evidence-based secondary prevention therapies is also very low.
- Most people suffering from NCDs incur out-of-pocket expenses for their healthcare costs.
- The annual total cost of diabetes care in India was estimated to be USD 32 billion.
In comparison to developed countries, NCDs, particularly CVD, diabetes and associated deaths in India occur at younger ages with related adverse health, economic and societal consequences. This is mainly attributable to the higher risk factor burden at younger ages, earlier disease onset (at least 10 years younger), premature mortality, and higher fatality rates of CVD-related complications. Indians also have a higher predisposition to develop CVD and diabetes at lower thresholds of overweight and obesity. Reports also indicate the reversal of the social gradient, whereby the poor suffer increased exposure to risks such as tobacco use, hypertension and acquiring diseases such as CVD and diabetes, a situation similar to that observed in developed countries that already have undergone health transitions. Compared to other countries, India suffers a very high loss in potential productive years of life because of premature CVD deaths in those aged 35–64: 9.2 million years were lost in 2000 and 17.9 million years are expected to be lost in 2030. These factors are further compounded by the poor lacking access to expensive medical care once disease occurs, leading to widening disparities in care and social inequity.

Current efforts to address NCDs

The health system has not yet fully re-oriented to effectively address the rising burden of NCDs, as the focus is still largely on providing acute care and not on providing chronic care. Thus, there are considerable inadequacies in service delivery both at the primary and secondary care levels. Heterogeneity of providers and wide variations in the quality, availability and accessibility of care have led to disparities, with the rich having access to the most expensive, evidence-based care and the poor lacking access to basic primary care. Efficient referral systems within the public sector as well as between the public and private sectors are also weak. Required emphasis on early diagnosis and evidence-based management approaches are also limited in both the public and private sectors. Furthermore, in the absence of financial risk protection, most people with NCDs pay out of pocket to cover their healthcare costs.

The government has initiated a national programme to address NCDs in addition to existing programmes that address cancer, tobacco, mental health and healthcare of the elderly. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) has hypertension and diabetes as two of the focus areas. It is being implemented in 100 districts and expected to cover the rest of the country within the 12th 5 year plan period. The NPCDCS aims at: a) assessment of risk factors, early diagnosis and appropriate disease management for high risk groups; and b) health promotion for the general population. Debates are ongoing on implementing universal health coverage strategies, health sector strengthening and reforms that can likely contribute to reducing NCDs.

India has also taken steps to discourage the use of tobacco. India is a signatory to the WHO Framework Convention on Tobacco Control (FCTC) and is implementing the Cigarettes and Other Tobacco Products Act, 2003 (COTPA), which requires smoking bans in public and work places, advertisement bans, prohibits sales to and by minors, and regulates the contents of tobacco products and graphical health warnings on tobacco product packages.
Many countries have now agreed to a goal of 25% reduction in NCDs by 2025 and to establish a global monitoring framework to measure progress. The way forward to address NCDs

Following the landmark United Nations High Level Meeting on NCDs in 2011, which concluded that NCD prevention and control is a high priority issue, many countries have now agreed to a goal of 25% reduction in NCDs by 2025 and to establish a global monitoring framework to measure progress toward this goal. The Ministry of Health and Family Welfare in India is in the final stages of establishing a national monitoring framework that is in alignment with the global framework and developing an action plan to prevent and control NCDs. The aforementioned global goal and the framework are anticipated to provide an impetus to prioritise NCD control efforts in India to improve population health. A cohesive national action plan that incorporates effective public health interventions to minimise risk factor exposure in the whole population and to reduce the risk of disease related events in individuals at high risk is necessary. Despite many challenges that are likely to be encountered, there are also opportunities to initiate actions required for attaining the WHO-UN goal of 25% reduction in NCD-related mortality. This combination of the population approach and the high risk clinical approach is synergistically complementary, cost-effective, and sustainable; and provides the strategic basis for early, medium and long term impact on NCDs in India in alignment with the aforementioned WHO-UN mandate.
References

About the authors
K. Srinath Reddy
Professor K. Srinath Reddy is presently President, Public Health Foundation of India (PHFI) and formerly headed the Department of Cardiology at All India Institute of Medical Sciences (AIIMS). He was appointed as the First Bernard Lown Visiting Professor of Cardiovascular Health at the Harvard School of Public Health in 2009. He is also an Adjunct Professor of the Rollins School of Public Health, Emory University and Honorary Professor of Medicine at the University of Sydney. PHFI is engaged in capacity building in Public Health in India through education, training, research, policy development, health communication and advocacy.

Sailesh Mohan
Dr Sailesh Mohan is currently a Senior Research Scientist and Associate Professor at the Public Health Foundation of India (PHFI). At PHFI, he is involved in research in non-communicable disease (NCD) prevention and control. Dr Mohan also serves as a Technical Expert to the World Health Organization, India on hypertension and NCD prevention and control.
The nutrition transition in India: Trends in dietary intake and associations with cardiometabolic outcomes

Shilpa Bupathiraju

India is facing an epidemic of diet-related non-communicable disease. Currently, India has the largest absolute number of persons with diabetes at approximately 61.3 million people. With rapid globalisation, urbanisation, and advances in agriculture and food production systems, India has witnessed a rapid nutrition transition in the past several decades. This transition is characterised by a shift away from the traditional Indian diet that was abundant in minimally processed foods, fruits and vegetables, to a diet that is rich in highly refined and processed grains, potatoes, salt, sugar-sweetened beverages, animal fats and products, and hydrogenated oils. When such changes are coupled with declining levels of physical activity in an increasingly urbanised environment, there has been a rapid escalation in the incidence of hypertension, obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Future research that is translational in nature is urgently needed to understand the effectiveness of a multi-pronged approach in preventing and controlling the rapid epidemic of cardiometabolic diseases such as type 2 diabetes and cardiovascular disease. Such research requires multi-disciplinary and multi-level coordination and will need to include all the relevant stakeholders, ie community, local governments, farmers, food establishments, worksites, policy makers, and clinicians in order to be truly effective.

Introduction

Research on diet and nutrition in the Indian subcontinent has primarily focused on the problem of undernutrition, specifically in children and women of child-bearing age. However, in recent years, India has been undergoing a rapid transition on economic, demographic, epidemiologic, and nutritional fronts. The direct impact of this transition has been on the incidence of cardiometabolic outcomes, especially type 2 diabetes and cardiovascular disease. The most recent National Family and Health Survey (NFHS-3: 2005–2006) data indicate that the prevalence of overweight or obesity among ever married women has increased from 11% in NFHS-2 (1998–1999) to 15%. The simultaneous occurrence of undernutrition and malnutrition implies that adults in India are suffering from the dual burden of malnutrition.

Nutrition transition is occurring at a much faster pace in low and middle-income countries like India than in the West. Reasons for this include a shift in occupation structures from labour-intensive occupations to more sedentary and less strenuous work, a rapid introduction of the mass media, and migration from rural to urban areas. In fact, recent data from the Indian Migration Study have shown that migration into urban areas is associated with increases in hypertension, obesity, and type 2 diabetes. Not surprisingly, among this group, migration also resulted in an increase in physical inactivity. Misra et al have described the nutrition transition in India as occurring in 3 stages. The first stage is characterised by a transition from traditional staple foods to items more prevalent in the Western diet, such as increased consumption of bread, cakes, and cookies. In the second stage, the effects of globalisation are much more marked and there is easy access to a variety of processed and fast foods. In the final stage, some individuals, especially those of the higher income group, realise the adverse effects of their dietary habits and transition to a healthier diet and lifestyle. In this report, we briefly review trends in major food sources and their associations with cardiometabolic outcomes.

Cereals

National trend data from the National Nutrition Monitoring Bureau (NNMB) surveys have shown a decline in cereal intake among rural, urban slum and urban middle income groups despite reductions in the cost of cereals.
The nutrition transition in India: Trends in dietary intake and associations with cardiometabolic outcomes

The declines in overall cereal intake are masked by increases in refined grains and a reduction in the consumption of traditional coarse-grains.

Per capita supply data from the Food and Agriculture Organization (FAO), which broadly reflect consumption patterns, indicate that the supply of coarse cereals like barley, sorghum, millet, and maize has declined drastically over the past four decades, while consumption of wheat and milled rice has increased (Figure 1A and 1B). Such changes are characterised by reductions in overall fibre intake, increases in overall energy-density, and increases in two important measures of carbohydrate quality (glycaemic index and glycaemic load) of the Indian diet. Highly polished white rice, whose use is prevalent among South Indians, has a high glycaemic index value of approximately 75–80. The high consumption of white rice, coupled with its high glycaemic index, results in a high glycaemic load in the Indian diet. We have previously shown that high glycaemic index and glycaemic load diets are associated with a 19% and 13% higher risk, respectively of type 2 diabetes.

Figures 1A and 1B: Trends in per capita supply (kilograms/year) of traditional coarse grains (A) and refined grains (B)

High intakes of dietary fibre were associated with a 69% lower odds ratio of type 2 diabetes.

Such shifts in cereal consumption have important public health implications in South Asians who have fewer beta cells and are, therefore, more likely to be predisposed to type 2 diabetes in response to a high demand for insulin. For example, in an urban sample of adults in Chennai, India, refined grain intake was associated with a nearly 5-fold higher odds (odds ratio, OR=5.31, 95% CI: 2.98–9.45) of newly diagnosed type 2 diabetes. Similarly, a high glycaemic index and high glycaemic load were associated with a 2.5 fold (95% CI: 1.42–4.43) and 4.25 fold (95% CI: 2.33–7.77) higher odds of newly diagnosed type 2 diabetes. On the other hand, high intakes of dietary fibre were associated with a 69% lower odds ratio (95% CI: 38%–85%) of type 2 diabetes emphasising the importance of switching back to traditional Indian diets that are rich in coarse grains and dietary fibre. In fact, randomised cross-over studies have conclusively shown that simple dietary changes, such as substituting brown rice for white rice, can have profound and immediate beneficial effects on glucose and insulin responses.
Starchy roots and tubers

Aggregate FAO data indicates that the per capita supply of starchy root has increased since 1961. However, when examining individual roots and tubers, consumption of potatoes and its products has dramatically increased while consumption of sweet potatoes has decreased (Figure 2). These changes indicate not only an increase in the energy density of the Indian diet, but a greater susceptibility to development of chronic disease. In India, consumption of potato is gradually shifting from the fresh market to processed products in the form of chips and French fries, which have a high glycaemic index and glycaemic load. Recently, McCain Foods, the world’s largest manufacturer of French fries and assorted potato snacks, has made a foray into the untapped Indian market. It is estimated that out of the total snacks, potato based products like French fries, wedges, and other Indian snacks claim a 30% share in the fast food industry with the fastest growth seen in the sale of frozen French fries. Studies in the US have shown that a daily serving of potatoes is associated with an 18% higher risk for type 2 diabetes. Every 2 servings/week of French fries was associated with a 16% higher risk of type 2 diabetes. More importantly, substituting one serving of whole grains for one serving of potatoes was associated with a 30% higher risk for type 2 diabetes. While the potato is classified as a vegetable, many agencies including the World Health Organization (WHO) recommend that individuals meet their recommended intake for vegetables by excluding potatoes. The effects of sweet potatoes on chronic disease are far less well understood. Although they have a lower glycaemic index and are good sources of fibre and other micronutrients, a recent systematic review concluded that there is insufficient evidence about the use of sweet potatoes for type 2 diabetes.

**Figure 2:** Trends in per capita supply (kilograms/year) of total and individual starchy roots

---

**Source:** Food and Agricultural Organization

---

**Sugars**

According to a recent report on India’s Sugar Policy and the World Sugar Economy, the per capita consumption of sugar in India in 2012 was 20.2kg, which is lower than the global average of 24.8kg. Yet, consumption of sugar in India is growing at a more rapid pace than the global average. In fact, in the last five decades, the production of sugar among Indians has risen from less than 3% to more than 20% of sugar produced globally. Food balance sheet data from the FAO demonstrate dramatic increases in per capita supply of raw sugar (Figure 3). Most of the sugar available in the open market is consumed in the form of sweets, baked goods, candies, ice cream and soft drinks.
Although carbonated beverage consumption has been historically low in India compared to the West, this is set to change as soft drinks companies are now targeting low and middle-income countries as the US market is saturated. For example, Coca-Cola plans to invest USD 5 billion in India by 2020 with the majority of this money being spent on increasing capacity in bottling units, expanding distribution, and brand building. Limited availability of clean drinking water in most areas and the increasing presence of refrigerators in small grocery stores have promoted the increased consumption among the new Indian middle-class who are now seeking to define themselves as part of a global consumer class.

Urban-rural differences in sugar intake highlight the effects of globalisation with urban participants reporting up to 35% higher sugar intake than their rural counterparts. Interestingly, India does not use any high fructose corn syrup and sucrose is the primary sugar that is used in most carbonated beverages. Most recent data from the Global Burden of Diseases Study indicate that sugar-sweetened beverages consumption is linked to 13,300 deaths from diabetes, 44,000 deaths from cardiovascular diseases, and 6,000 deaths from cancer.

Sales of sugar-sweetened beverages in India have increased by 13% every year since 1998, exceeding 11 litres per capita per year. It is estimated that if sugar-sweetened beverage consumption continued to increase linearly in accordance with secular trends, a 20% sugar-sweetened beverage excise tax would be expected to prevent nearly 11.2 million new cases of overweight and obesity (representing a 3% decline), and 400,000 cases of type 2 diabetes (representing a 1.6% decline) over the decade 2014–2023.

**Source:** Food and Agricultural Organization

---

**Fats and oils**

Although precise data on consumption of oils and fats at the individual and household level are missing, national aggregate statistics show high consumption of unhealthful oils. NSSO survey data showed that there has been an increase in the per capita consumption of edible oil; between 1993–94 and 2004–2005, there has been a rise in oil consumption both in rural and urban areas. Time trends in the per capita supply fats and oils between 1961 and 2009 have shown that the supply of vegetable oils has nearly doubled while those of animal fats have increased threefold. Among animal fats, per capita supply of clarified butter or ghee, which contains over 80% of saturated fatty acids, has seen about a fourfold increase (Figure 4). While exact household and individual level data on oil consumption are unavailable, national aggregate data indicate that the share of raw oil, refined oil and vanaspati oil in the total edible oil market is estimated at 35 percent, 55 percent, and 10 percent, respectively. Vanaspati oil or ghee is fully or partially hydrogenated.
vegetable cooking oil that has a longer shelf life and is often used in food establishments and households as a cheaper alternative to clarified butter or ghee. Palm oil, rich in saturated fats, is the primary oil used for production of vanaspati.

The Food Safety and Standards Authority of India has issued a proposal to limit trans fat content of hydrogenated vegetable oil to a maximum of 10%, which will be further reduced to 5% in 3 years\(^\text{17}\). However, there are no specifications for trans fats in other edible oils and fats. A recent analysis of trans fatty acid content in edible oils and fats in India revealed that, except in sunflower oil, the average trans fatty acid content in both mustard and soybean oil was above the prescribed limit (2%) of Denmark. The average trans fatty acid content in branded and unbranded butter was 15.1% and 18.9% respectively, which exceeded the prescribed Denmark limit by 3.5-fold to over 10-fold in branded and unbranded samples\(^\text{18}\). These data imply that trans fat intake is steadily increasing in the Indian diet given that the consumption of edible oil and animal fat is increasing. This represents a significant public health concern as there is no safe upper limit for trans fat intake. At the same time, no regulations exist for trans fats in packaged foods. However, the Government of India now requires manufacturers to list trans fat on the nutrition label if it exceeds 0.2 grams per serving. Still, India’s lax food labelling laws have allowed manufacturers to define their own serving sizes. Therefore, many foods which have considerable amounts of trans fats (such as potato chips) are now labelled trans fat free by presenting nutrition labels for unreasonably small serving sizes.

The overall prevalence of hypertension in India was reported as 29.8%, indicating that over 370 million Indian adults suffer from elevated blood pressure.

Dietary salt

Based on a recent meta-analysis of population-based studies, the overall prevalence of hypertension in India was reported as 29.8%, indicating that over 370 million Indian adults suffer from elevated blood pressure. Estimates were higher in urban compared to rural areas (33.8% vs 27.6%), indicating the effects of rapid urbanisation on the country’s changing cardiovascular risk profile\(^\text{19}\). High salt intake is an established risk factor for cardiovascular disease. The average salt consumption in India is estimated to be between 9–12 grams/day with higher intakes seen in urban compared to rural areas\(^\text{20, 21}\). This level of consumption is far above the joint WHO and FAO recommended consumption of less than 5 grams/day\(^\text{22}\). Such high levels of consumption can partly be attributed to consumption of foods such as pickles (fruits and vegetables with spices that are preserved in salt and oil), papadams (crisp, thin seasoned discs with salt, spices and oil usually served as an accompaniment), namkeens (a salty Indian snack) and chutneys.
As income levels continue to increase, consumption of processed and ready to eat foods, which are typically high in sodium, has gone up. The efficacy of reducing salt consumption in lowering blood pressure has been well established, although the long-term effects on incidence of cardiovascular disease are less well understood.

Using a Markov prediction model, Basu et al. estimated that if current consumption levels of salt remain unaltered in India, there would be approximately 8.3 million myocardial infarctions, 830,000 strokes, and 2 million deaths per year among Indian adults aged 40–69 years over the next three decades. However, a 25% reduction in salt intake (representing reduction of 0.1 g/year over the next 3 decades) would result in an annual reduction of 350,000 myocardial infarctions (4.6%), 48,000 strokes (6.5%), and 81,000 deaths (4.9%) among this group.

**Fruits and vegetables**

Although India is one of the largest producers of fruits and vegetables, consumption remains much below WHO recommended levels. For example, in a study of urban adults in Chennai, overall consumption of fruits and vegetables was 265 g/day. In another study of urban residents in Jaipur, nearly 70.3% of adults consumed <3 helpings of fruits and vegetables per day. Despite a high prevalence of predominantly plant-based diets, consumption of fruits and vegetables remains low among Indians. Analysis of the INTERHEART data indicate that only 26.5% of South Asians consumed fruits and vegetables on a daily basis compared to 45.2% of control arm patients from the remaining 47 non-South Asian countries. National data from the National Nutrition Monitoring Bureau reveal that intakes of green leafy vegetables continue to be much below the recommended daily allowance (only one-third) of 40 g/day. Similarly, intake of fruits is extremely low (Figure 5). Low fruit and vegetable intake has been recognised by the WHO as one of the major risk factors for cardiovascular disease. In a case-control study conducted in New Delhi and Bangalore, persons consuming a median of 3.5 servings/week had a 67% lower risk (95% CI: 36%–83%) of ischemic heart disease compared to those consuming 0.5 servings/week.

Using an ecological study design, Gupta et al. found that cardiovascular mortality was higher among Indian states with lower intakes of fruit and vegetables. In a population-based cross-sectional study on a representative population of Chennai in Southern India, a higher intake of fruit and vegetables explained nearly half (48%) of the protective effect against CVD risk factors, such as systolic blood pressure, BMI, waist circumference, total cholesterol and LDL-cholesterol. Given that fruit and vegetable intake continues to be below national and international recommendations, despite their abundance, policy efforts should focus on education and behavioural changes to promote fruit and vegetable consumption.
Conclusion

India is in the midst of a public health crisis. Incidence of cardiovascular disease and type 2 diabetes are escalating as global free trade continues to fuel rapid economic and nutrition transitions, especially in urban settings. While rural India is still in the early stages of the nutrition transition, urban India is in the midst of the second stage of the nutrition transition where Indian diets are more westernised and there is widespread access to highly processed foods. A direct consequence of these transitions is the sudden increases in the prevalence of type 2 diabetes and cardiovascular disease.

The economic impact of these transitions is estimated to cost the country 236.6 billion international dollars for type 2 diabetes and cardiovascular disease alone. While it is now well established that increases in non-communicable diseases are fuelled by modifiable risk factors such as diet and physical activity, there is a paucity of research on the role of diet and lifestyle in the prevention of cardiometabolic outcomes in India.

Key research areas include: (i) understanding the feasibility, acceptability and efficacy of simple dietary interventions such as substituting brown rice for white rice on cardiometabolic risk, (ii) mechanistic research to understand the lower age of onset of cardiovascular disease and type 2 diabetes and the lower threshold for various risk factors among South Asians, (iii) the effect of policy changes such as taxation on sugar sweetened beverages and fast foods, as well as changes in food labelling laws on the incidence of type 2 diabetes and cardiovascular disease, (iv) the effect of educational campaigns via local and social media to discourage consumption of sugar-sweetened beverages and refined grains and to promote consumption of healthy foods and increase physical activity, (v) the effect of worksite interventions including provision of healthy food choices in the cafeteria, structured physical activity and behaviour change education on markers of cardiometabolic risk, and (vi) the effect of improvements in the built environment with parks, walkable, and bike-friendly streets and neighbourhoods, periodic celebrations of walk/bike days, and community yoga programmes on body weight and cardiometabolic risk factors. Such research needs to involve all sectors of the community, including local government bodies, the food and beverage industry, food establishments, worksites, local celebrities and leaders, farmers, and agricultural producers. Future research should be translational (from cells to communities) in order to develop a successful multi-pronged approach to prevent the epidemic of type 2 diabetes and cardiovascular disease.
The nutrition transition in India: Trends in dietary intake and associations with cardiometabolic outcomes

References


17. Food Safety and Standards Authority of India. Regulation of Trans Fatty Acids (TFAs) in Partially Hydrogenated Vegetable Oils (PHVOs). Internet: http://www.fssai.gov.in/Portals/0/Regulation_of_TFA_.pdf


About the author

Shilpa Bhupathiraju
Dr. Shilpa Bhupathiraju is a Research Associate in the Department of Nutrition at the Harvard School of Public Health. Bhupathiraju received her PhD in Nutritional Epidemiology from the Friedman School of Nutrition Science and Policy at Tufts University in 2011. As a Research Fellow at HSPH, she has been examining the dietary and lifestyle predictors in the prevention and development of cardiovascular disease and type 2 diabetes in the Harvard cohorts. Bhupathiraju received an American Heart Association postdoctoral fellowship grant to examine the association of quantity and variety in fruit and vegetable intake in the prevention of cardiovascular disease in both the Women’s Health Initiative and the Harvard cohorts. As a Swiss Re fellow, Bhupathiraju explored the association between fruits and vegetable intake and cardiometabolic risk using data from the India Migration Study. She is especially interested in understanding how the nutrition transition in India is affecting rates of cardiovascular disease and type 2 diabetes in India.
Health risk factors in the adult Mexican population

Hiram Beltrán-Sánchez

The Mexican population has experienced dramatic changes in their physiological status resulting from major shifts in diet accompanied by changes in the epidemiologic profile. Infectious diseases were once predominant, but now chronic conditions are more prevalent. The shift from under-nutrition (low-calorie consumption) to over-nutrition (higher than needed calorie consumption) occurred over a short period of time and the health consequences are beginning to emerge. There is considerably high prevalence of health risk factors (e.g., overweight/obesity and hypertension) and chronic conditions (e.g., diabetes) in the adult population. Particularly important is the high prevalence of overweight/obesity, hypertension, and diabetes among young adults aged 30–49. Nonetheless, major strides have been made in the last decade by implementing public health policies to ameliorate the health consequences of adverse health risk factors. If these policies reach their goals, we may see important improvements in health and well-being of the Mexican population in the years to come, which will have important consequences for health care costs.

Introduction

The Mexican population has experienced important improvements in health and survival since the mid-20th century. For instance, declines in mortality rates below age 5 contributed to about half of the 26-year increase in life expectancy at birth between 1940 and 1990\(^1\); while the prevalence of stunting in children under age 3 declined by about 22\% between 1988 and 1999\(^2\). Although important, these improvements have also been accompanied by considerable increases in the prevalence of health risk factors (e.g., overweight/obesity and hypertension) and chronic conditions (e.g., diabetes) in the adult population.

Changes in the health status of the Mexican population have resulted from two general forces – (i) the demographic and epidemiologic transition and (ii) changes in nutrition and income.

Demographic and epidemiologic transition

The demographic and epidemiologic transition is characterized by a shift from high to low mortality and fertility. Infectious diseases have also declined, while non-communicable diseases have increased. Changes in the health status of the Mexican population have resulted from two general forces – (i) the demographic and epidemiologic transition and (ii) changes in nutrition and income. These changes have led to major shifts in national patterns of health and disease because infectious diseases are no longer the leading causes of death and morbidity. Now chronic conditions, such as diabetes and cardiovascular disease, are more prevalent in Mexico and are currently the leading causes of death in the adult population\(^3\). Moreover, in the last decade, several risk factors for chronic disease, such as hypertension and cholesterol, seem to be on the rise with an increasing number of people being afflicted by overweight and obesity\(^4\).
Many populations across the globe have experienced dramatic changes in their physiological status resulting from major shifts in diet, growing concentration of jobs requiring low energy expenditure and environmental change.

Traditional dietary habits have changed and the traditional Mexican diet based on corn and beans, typical of rural areas in the mid-1980s, has now been replaced by high caloric industrially produced foods such as refined carbohydrates and sugar-sweetened drinks, as well as an increase in fat consumption.

The shift from under-nutrition to over-nutrition has occurred over a short period of time.

Nutrition transition

In recent years, many populations across the globe have experienced dramatic changes in their physiological status resulting from major shifts in diet, growing concentration of jobs requiring low energy expenditure and environmental change. The nutrition transition is described as a shift from high prevalence of under-nutrition to the preponderance of diets related to chronic diseases. This transition typically results from rapid urbanisation processes and economic growth, concentration of jobs requiring low energy expenditure due to technological changes and innovations, and changes in food patterns and dietary intake, such as increased consumption of high caloric processed foods. For low and middle-income countries, improved nutrition in the last decades had a major role in reducing infant and childhood mortality during the demographic and epidemiologic transition; for example, increased nutrition improves both resistance to disease and resources available for recovery from infection. Nonetheless, many of these countries experienced improved nutrition resulting from a rapid change in their diet and this shift is having a detrimental effect on the health status of the population due to excess calorie consumption.

Mexicans have not escaped this trend and they too have experienced major dietary changes in the last decades. Traditional dietary habits have changed in that people are more likely to eat away from home and the traditional Mexican diet based on corn and beans, typical of rural areas in the mid-1980s, has now been replaced by high caloric industrially produced foods such as refined carbohydrates and sugar-sweetened drinks (e.g., soda, fruit juices etc) as well as an increase in fat consumption. For instance, between 1988 and 1999, there was an increase of about 29% in total energy consumption from fat, while mean household purchases per adult equivalent indicated an increase of 37% and 6% in sugars and refined carbohydrates, respectively, between 1984 and 1998, along with a decline of about 29% in the purchase of fruits and vegetables. Although urban areas first experienced these dietary changes, they have now swept throughout Mexico. In the 1990s, more urban areas typically located in the Northern part of the country and Mexico City had a greater increase in total energy consumption from fat relative to the less urban areas of the South; however, in recent years, this pattern has become more homogeneous across the country, resulting from increasing fat consumption rates in the South.

The shift from under-nutrition (low calorie consumption) to over-nutrition (higher than needed calorie consumption) in the Mexican population has occurred over a short period of time and the health consequences are beginning to emerge.
Major health risk factors in the adult population

Figure 1 shows results from nationally representative health surveys in Mexico in 2000, 2006 and 2012 for obesity, underweight, and hypertension for males and females among insurance relevant age groups. Obesity and underweight are defined as body mass index (BMI) $\geq 30$ or BMI $<18.5$, respectively, while hypertension corresponds to blood pressure $>140/90$ mmHg and/or previous diagnosis of the condition.

Figure 1:

Note: Obesity and underweight are defined as body mass index (BMI) $\geq 30$ or BMI $<18.5$, respectively, while hypertension corresponds to blood pressure $>140/90$ mmHg and/or previous diagnosis of the condition.

Health risk factors in the adult Mexican population

Obesity
Prevalence of adult obesity in Mexico has grown at an unprecedented pace during the last two decades, reaching the highest level (33%) in the Latin America region in 2012. The country attained this top ranking fuelled by a very rapid rate of growth: in 2000, the prevalence of obesity among males and females was about 70% of what it was in 2012, which suggests that obesity prevalence will double in about 19 years. Figure 1 clearly shows that obesity prevalence continues to increase in the last decade across all adult ages among females, with a peak for those aged 50–59, while among males, this pattern is true for those younger than 60. More worrisome are the high prevalence levels of obesity among younger adults in recent years, particularly females. For example, about one-fourth, one-third and almost half of females aged 20–29, 30–39 and 40–49, respectively, were obese in 2001, with males showing slightly lower values. In addition, obesity appears to be more prevalent in urban areas and among people with low levels of education. On the other hand, underweight has reached an all-time low in the country, with prevalence rates below 5% across all ages, although underweight remains more prevalent in the southern part of the country.

Hypertension
Contrary to the fast increase in body weight in the adult Mexican population, hypertension prevalence slightly declined among the young, but it increased among the old. Overall, males tend to have higher prevalence of hypertension at younger ages (20–39), but the opposite is true at older ages (60+). For example, in 2012, about 20% and 15% of Mexican males and females aged 30–39 had hypertension, with a very rapid increase after this age reaching a level of about 60% over age 60. Some evidence indicates that about three-fourths (73%) of hypertensive individuals in 2012 received medical treatment for this condition. In addition, there are marked differences in hypertension prevalence within the country, with rural areas and the northern part of Mexico showing higher prevalence rates and people with low levels of education showing higher likelihood of being hypertensive. Importantly, there is a strong link between obesity and hypertension in the Mexican adult population in that obesity has been shown to triple the likelihood of hypertension.

Diabetes
Type-2 diabetes (i.e., diabetes mellitus) is a major chronic condition affecting the adult Mexican population. Its prevalence in 2006 was roughly 14% after more than doubling during the prior 13 years. However, the prevalence among older adults is much higher, reaching about 19% and 24% among those aged 50–59 and 60–79, respectively, in 2012.
Mexicans are experiencing a rapid change in nutrition. While important, this shift has also been accompanied by a higher than needed total calorie consumption with detrimental health consequences.

The rates of early obesity and hypertension are still climbing.

The Ministry of Health has many programmes that include prevention as a major component, with a focus on obesity, diabetes, high blood pressure and cancer.

Mexico passed new legislation that bans tobacco advertising and mandates pictorial warning labels on tobacco cartons, while a ban on smoking in public enclosed places and workplaces was established in 2008.

Mexico has also implemented a tax on sugary drinks and high calorie food products.

Discussion

Similar to populations in other middle-income countries, Mexicans are experiencing a rapid change in nutrition. While important, this shift has also been accompanied by a higher than needed total calorie consumption with detrimental health consequences. Overweight and obesity among adults, for example, is among the highest in the world, with over 70% of adults having BMI over 25, although there has been a levelling off in recent years. Increases in body weight have led to a rise in associated co-morbidities such as hypertension and diabetes. More importantly, these co-morbidities are quite prevalent among young adults.

Hypertension, which places one at a high risk for cardiovascular events, was present in about one-fifth and one-third of Mexicans aged 30–39 and 40–49 in 2012, respectively; by age 60, hypertension affected more than half of the population. Although diabetes prevalence was much lower than hypertension, there is a major burden associated with the disease due to high treatment costs, its fast progression and its high death toll.

More worrisome, perhaps, is the recent evidence suggesting that among adults the prevalence of high risk factors is likely to get worse before it gets better. The rates of early obesity and hypertension are still climbing and early high risk factors are precursors of detrimental health outcomes later in life. For instance, the prevalence of obesity increased for both males and females aged 5–11 between 1999 and 2012, from 9.6% and 8.3% in 1999 to 17.4% and 11.8% in 2012, respectively, and increasing body weight has also been observed among adolescents, particularly in urban areas. Similarly, the prevalence of hypertension was already about 11% in the late 1990s in a sample of junior high school students (aged 12–16) in Mexico City. In addition, young adults now will be the older adults of the next decades; the high prevalence rates of hypertension and diabetes among the former suggests that older adults in the coming years are likely to have a high number of health risk factors and co-morbidities.

The way forward to address population health in Mexico

Major strides have been made in Mexico to implement public health policies to ameliorate the health consequences of adverse health risk factors. For instance, the Ministry of Health has many programmes that include prevention as a major component, with a focus on obesity, diabetes, high blood pressure and cancer. There is a programme for each disease providing general management and prevention guidelines for government health service providers to follow.

Additionally, public health and tobacco control programmes have been substantially strengthened in the country since the late 1990s when member states of the WHO adopted the Framework Convention on Tobacco Control in 1999. Mexico passed new legislation that bans tobacco advertising and mandates pictorial warning labels on tobacco cartons, while a ban on smoking in public enclosed places and workplaces in Mexico City was established in 2008 and extended to the whole country later that year. Moreover, taxes on cigarettes have substantially increased. After a tax increase in 2007, the price of cigarettes rose by about 10%; in that year, there was a 29% decline in the average number of cigarettes smoked per day.

More recently, Mexico implemented a tax on sugary drinks (1 peso – about US$0.08 or €0.04 – per litre) and on high calorie content products (from 5% to 8%) that took effect in January 2014. It is still too early to evaluate the effect of the latter tax policy on health outcomes, but preliminary evidence suggests there has been a decline in soda consumption.
Importantly, a major health care reform was launched in 2004 called the “National System of Health-related Social Protection,” which aims to achieve universal health care coverage in the country by providing health insurance to people who are not part of or linked to the formal economically active population. Seguro Popular – the most common name used for the programme – offers heavily to fully-subsidised health insurance to Mexicans without other forms of steady access to health care, and covers a large variety of health conditions and treatments. Seguro Popular dramatically increased health care coverage during the last decade from 40% of the population in 2000 to 65% in 2010[^27] and there is evidence that it has also helped decrease health care costs (e.g., out of pocket expenses) for many families[^28]. Similarly, access to health insurance, and the expansion of Seguro Popular in particular, have been shown to play a major role in diagnosis and treatment of diabetes among older adults (aged 50+)[^29].

**Conclusion**

Mexico experienced a change from under-nutrition (low-calorie consumption) to over-nutrition (higher than needed calorie consumption) in the last three decades. These changes have resulted in a considerably high prevalence of health risk factors (e.g., overweight/obesity and hypertension) and chronic conditions (e.g., diabetes) in the adult population. Despite many challenges encountered by policy makers, they have enacted several public health policies to ameliorate the health consequences of adverse health risk factors, including major health care reform, a smoking ban and taxation of tobacco products, as well as a recent tax on sugary drinks and high calorie content products. If these policies reach their goals, we may see important improvements in health and well-being of the Mexican population in the years to come, which will have important consequences for health care costs.

**Acknowledgement**

The author acknowledges support from Harvard and Swiss Re as a member of the SEARCH project as well as the Center for Demography of Health and Aging at the University of Wisconsin-Madison.
References


Health risk factors in the adult Mexican population


About the author
Hiram Beltrán-Sánchez
Hiram Beltrán-Sánchez is a Research Associate at the Center for Demography of Health and Aging at the University of Wisconsin-Madison. His research focuses on studying national patterns of mortality, morbidity and health using biomarker indicators and multidisciplinary approaches to identify salient characteristics associated with the observed health profiles in low and middle-income countries, with particular emphasis on Mexico.
Acknowledgement

In January 2013, Swiss Re and the Harvard School of Public Health (HSPH) launched the research collaboration SEARCH, the Systematic Explanatory Analyses of Risk factors affecting Cardiovascular Health, to better understand the relationship between risk factors and health outcomes. As one of the world’s leading reinsurers, Swiss Re seeks more accurate projections of global morbidity and mortality. HSPH seeks to better understand the most important determinants of health and to improve health status globally.

Swiss Re, Swiss Re Foundation and the Swiss Re Centre for Global Dialogue (CGD) have funded this joint research initiative which came to an end in July 2014. The focus of SEARCH was on risk factors for cardiovascular disease and stroke in Brazil, Mexico, China and India. These four countries are flagships for rapid development and rapid evolution of a variety of health risk factors that will determine morbidity, mortality and longevity. The postdoctoral fellows listed below were awarded grants to conduct research based on existing data sets and cohorts, and were accompanied by mentors from HSPH and Swiss Re.

This publication would not have been possible without the support of a number of people.

We would like to especially thank the fellows, mentors, collaborators and the organising committee for their contributions.

HSPH fellows
Hillel Alpert
Hiram Beltrán-Sánchez
Shilpa Bhupathiraju
Daniel Corsi
Martin Lajous
Yanping Li
Grégorie Mielke
Jennifer Nguyen
Marcia Otto
Claudia Suemoto
Hongyu Wu

HSPH mentors
Gregory Connolly
Goodarz Danaei
Douglas Dockery
Frank Hu
I-Min Lee
Dariush Mozaffarian
Lu Qi
Subu Subramanian
Qi Sun

Swiss Re collaborators
Himanshu Bhatia
Hueyfang Chen
Brian Ivanovic
Ken Krause
Eduardo Lara
David Lu
Xiaojie Wang
Urs Widmer
Monica Wilson

Other collaborators
Marcia Castro
Pedro Hallal
Ted Henson
David Hunter
William Hsiao
Anne Lusk
Sailesh Mohan
C. Arden Pope III
Walter Willett

Lown Institute collaborators
Bernard Lown
Srinath Reddy
Vikas Saini

Organising committee
Joseph Brain, HSPH
Douglas Dockery, HSPH
Annabelle Hett, Swiss Re CGD
Frank Hu, HSPH
Christoph Nabholz, Swiss Re CGD
Andreas Obrist, Swiss Re CGD
Helen Chung Patterson, Swiss Re
Daniel Ryan, Swiss Re
Nancy Long Sieber, HSPH
Michelle Williams, HSPH
Thomas Zeltner, WHO
Swiss Re

The Swiss Re Group is a leading wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. Dealing direct and working through brokers, its global client base consists of insurance companies, mid-to-large-sized corporations and public sector clients. From standard products to tailor-made coverage across all lines of business, Swiss Re deploys its capital strength, expertise and innovation power to enable the risk taking upon which enterprise and progress in society depend.

Harvard School of Public Health brings together dedicated experts from a wide range of disciplines to educate new generations of global health leaders and produce powerful ideas through rigorous research that can transform the lives and health of people everywhere. Each year more than 400 faculty members at HSPH teach 1200-plus full-time students from around the world, as well as train thousands more through online and executive education activities. Our educational programs and research efforts range from the molecular biology of AIDS to the epidemiology of cancer; from violence prevention to healthy lifestyles and nutrition; from maternal and children’s health to environmental health; from US health policy to international health and human rights.

The Swiss Re Centre for Global Dialogue is a platform for the exploration of key global issues and trends from a risk transfer and financial services perspective. Founded by Swiss Re, one of the world’s largest and most diversified reinsurers, in 2000, this state-of-the-art conference facility positions Swiss Re as a global leader at the forefront of industry thinking, innovation and worldwide risk research. The Centre facilitates dialogue between Swiss Re, its clients and others from the areas of business, science, academia, and politics.

Swiss Re Foundation is a non-profit organisation committed to care and concern for society and the environment. Launched in 2012 by global re/insurer Swiss Re, the Foundation aims to make people more resilient towards natural hazards, climate change, population growth, water scarcity and pandemics, along with other challenges to society’s security, health and prosperity. It also supports community projects and employee volunteering in locations where Swiss Re has offices.